<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Brief Funct Genomics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Brief Funct Genomics</journal-id>
    <journal-id journal-id-type="publisher-id">bfgp</journal-id>
    <journal-title-group>
      <journal-title>Briefings in Functional Genomics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">2041-2649</issn>
    <issn pub-type="epub">2041-2657</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10467634</article-id>
    <article-id pub-id-type="pmid">36124841</article-id>
    <article-id pub-id-type="doi">10.1093/bfgp/elac030</article-id>
    <article-id pub-id-type="publisher-id">elac030</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Protocol Article</subject>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01140</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Dynamic cancer drivers: a causal approach for cancer driver discovery based
on bio-pathological trajectories</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Cifuentes-Bernal</surname>
          <given-names>Andres M</given-names>
        </name>
        <!--andres.cifuentes_bernal@mymail.unisa.edu.au-->
        <aff><institution>UniSA STEM Unit, University of South Australia</institution>,
<addr-line>Mawson Lakes Blvd, 5095, South Australia </addr-line>, <country country="AU">Australia</country></aff>
        <xref rid="cor1" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Pham</surname>
          <given-names>Vu V H</given-names>
        </name>
        <aff><institution>UniSA STEM Unit, University of South Australia</institution>,
<addr-line>Mawson Lakes Blvd, 5095, South Australia </addr-line>, <country country="AU">Australia</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Xiaomei</given-names>
        </name>
        <aff><institution>UniSA STEM Unit, University of South Australia</institution>,
<addr-line>Mawson Lakes Blvd, 5095, South Australia </addr-line>, <country country="AU">Australia</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Lin</given-names>
        </name>
        <aff><institution>UniSA STEM Unit, University of South Australia</institution>,
<addr-line>Mawson Lakes Blvd, 5095, South Australia </addr-line>, <country country="AU">Australia</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Jiuyong</given-names>
        </name>
        <aff><institution>UniSA STEM Unit, University of South Australia</institution>,
<addr-line>Mawson Lakes Blvd, 5095, South Australia </addr-line>, <country country="AU">Australia</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Duy Le</surname>
          <given-names>Thuc</given-names>
        </name>
        <!--thuc.le@unisa.edu.au-->
        <aff><institution>UniSA STEM Unit, University of South Australia</institution>,
<addr-line>Mawson Lakes Blvd, 5095, South Australia </addr-line>, <country country="AU">Australia</country></aff>
        <xref rid="cor1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="cor1">Corresponding authors: Andres M. Cifuentes-Bernal, UniSA STEM, University
of South Australia, Mawson Lakes, SA 5095, Australia. E-mail:
<email>andres.cifuentes_bernal@mymail.unisa.edu.au</email>,
<email>andresm12@gmail.com</email>; Thuc Duy Le,
<email>thuc.le@unisa.edu.au</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>11</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2022-09-19">
      <day>19</day>
      <month>9</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>19</day>
      <month>9</month>
      <year>2022</year>
    </pub-date>
    <volume>21</volume>
    <issue>6</issue>
    <fpage>455</fpage>
    <lpage>465</lpage>
    <history>
      <date date-type="received">
        <day>18</day>
        <month>5</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>08</day>
        <month>8</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>23</day>
        <month>8</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022. Published by Oxford University
Press.</copyright-statement>
      <copyright-year>2022</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted
reuse, distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="elac030.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>The traditional way for discovering genes which drive cancer (namely cancer drivers)
neglects the dynamic information of cancer development, even though it is well known that
cancer progresses dynamically. To enhance cancer driver discovery, we expand cancer driver
concept to dynamic cancer driver as a gene driving one or more bio-pathological
transitions during cancer progression. Our method refers to the fact that cancer should
not be considered as a single process but a compendium of altered biological processes
causing the disease to develop over time. Reciprocally, different drivers of cancer can
potentially be discovered by analysing different bio-pathological pathways. We propose a
novel approach for causal inference of genes driving one or more core processes during
cancer development (i.e. dynamic cancer driver). We use the concept of pseudotime for
inferring the latent progression of samples along a biological transition during cancer
and identifying a critical event when such a process is significantly deviated from normal
to carcinogenic. We infer driver genes by assessing the causal effect they have on the
process after such a critical event. We have applied our method to single-cell and bulk
sequencing datasets of breast cancer. The evaluation results show that our method
outperforms well-recognized cancer driver inference methods. These results suggest that
including information of the underlying dynamics of cancer improves the inference process
(in comparison with using static data), and allows us to discover different sets of driver
genes from different processes in cancer. R scripts and datasets can be found at <ext-link xlink:href="https://github.com/AndresMCB/DynamicCancerDriver" ext-link-type="uri">https://github.com/AndresMCB/DynamicCancerDriver</ext-link></p>
    </abstract>
    <kwd-group>
      <kwd>Driver genes</kwd>
      <kwd>dynamics</kwd>
      <kwd>causality</kwd>
      <kwd>pseudotime</kwd>
      <kwd>causal impact</kwd>
      <kwd>cancer</kwd>
    </kwd-group>
    <counts>
      <page-count count="11"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <title>1 Introduction</title>
    <p>Cancer development is traditionally linked to changes at genome level, commonly known as
‘driver’ mutations, that confer proliferative advantage to some cells over others, usually
leading to a neoplasm [<xref rid="ref1" ref-type="bibr">1</xref>]. Among the mutations that
can be found in cancer tumours, a minimum number promotes tumourigenesis, especially in
comparison with the vast number of passenger mutations that do not confer superiority to
cancer cells [<xref rid="ref2" ref-type="bibr">2</xref>]. For this reason, most efforts in
recent decades have been focused on distinguishing between genes harbouring driver mutations
and genes with mutations that do not provide selective advantages to the cell [<xref rid="ref3" ref-type="bibr">3</xref>, <xref rid="ref4" ref-type="bibr">4</xref>].</p>
    <p>The impact of a genetic aberration can be reflected on other genes besides the mutated gene
as genes interact in complex biological networks [<xref rid="ref5" ref-type="bibr">5</xref>,
<xref rid="ref6" ref-type="bibr">6</xref>]. As a result, a mutated gene can affect gene
products further than its own, even in genes carrying no defects [<xref rid="ref7" ref-type="bibr">7</xref>]. Taking this into consideration, some methods of cancer drivers
discovery have integrated biological network information [<xref rid="ref8" ref-type="bibr">8</xref>, <xref rid="ref9" ref-type="bibr">9</xref>]. These approaches have become
popular in recent years due to the fact they can integrate and summarize different layers of
data in an easy and comprehensible way. A detailed review and comparison of cancer drivers
discovery methods can be found in [<xref rid="ref10" ref-type="bibr">10</xref>].</p>
    <p>The fundamental hypothesis in this paper is that ‘incorporating the dynamic aspect of
biological processes driving cancer progression allows us to detect <italic toggle="yes"><bold>cancer
drivers</bold></italic> that are not identifiable by methods based on data that neglects
the dynamic’, and neglecting dynamics during inference process reduces the spectrum of
cancer drivers that can be detected from observational data. Formally, throughout this paper
we name a gene driving one or more core processes over cancer progression as
<italic toggle="yes"><bold>dynamic cancer driver</bold></italic> (DCD for short). Genes driving such
processes may not be mutated as not all cancer drivers harbour driver mutations (Figure
<xref rid="f1" ref-type="fig">1</xref>, please see [<xref rid="ref10" ref-type="bibr">10</xref>] for a review). Moreover, anomalies in biological processes leading to cancer
development may occur at different stages of cancer progression, and thus the set of cancer
drivers may not be a fixed set throughout the progression of the disease.</p>
    <fig position="float" id="f1">
      <label>Figure 1</label>
      <caption>
        <p>Graphical representation of the overlap of different categories of cancer drivers
(adapted from [<xref rid="ref10" ref-type="bibr">10</xref>]). Genes with driver
mutations are cancer drivers. Recent findings have shown some genes without driver
mutations can also drive cancer progression. Genes driving biological processes leading
to cancer (i.e <bold><italic toggle="yes">dynamic cancer drivers</italic></bold>, DCD for short) are
not necessary mutated. Additionally, different biological core processes (shorten in the
figure as bio-process) are driven by different set of genes.</p>
      </caption>
      <graphic xlink:href="elac030f1" position="float"/>
    </fig>
    <p>Our hypothesis is based on the fact that mutational and network-based approaches infer
cancer drivers without using the dynamical aspect of the disease. Cancer, as well as a large
number of other diseases, is a compendium of heterogeneous processes. Cancer is considered
to be driven by irregularities (including mutations) at different molecular levels, such as
genetic, epigenetic and transcriptomic levels [<xref rid="ref11" ref-type="bibr">11</xref>].
Those irregularities alter normal biological processes. As a result, phenotypes linked to
the disease are the consequence of various bio-pathological processes occurring within a
complex network [<xref rid="ref7" ref-type="bibr">7</xref>], evolving through time in a
dynamical way.</p>
    <p>Dynamical information (in the sense of information generated by a dynamic system) of some
biological processes can be directly obtained from time series datasets (e.g. [<xref rid="ref12" ref-type="bibr">12</xref>, <xref rid="ref13" ref-type="bibr">13</xref>]). But
reliable disease-related real time series datasets are rare in practice as they are costly
and technically difficult to get. Moreover, disease progression is influenced by a wide
range of factors that cannot be completely replicated artificially. Additionally, most time
series datasets for biological processes are obtained from controlled experiments in
laboratories; they can usually represent accurately few processes of the disease progression
at a time. For those reasons, the vast majority of cancer-related datasets are obtained from
cross-sectional studies, where data (known as cross-sectional or static data) are collected
at one single instant during the disease.</p>
    <p>Capturing useful dynamical information from cross-sectional cancer data for drivers
discovery becomes the key step for exploiting dynamic information in static data. The
<italic toggle="yes">pseudotime</italic> concept, originally developed for single-cell data, is a good
candidate for extracting dynamical information from biological processes. The basic idea of
<italic toggle="yes">pseudotime</italic> is that given a collection of heterogeneous samples (usually
single cells), disperse along a biological transition (a biological progression), each
sample can be scored to reflect its stage in such a progression [<xref rid="ref14" ref-type="bibr">14</xref>]. Recently, it has been found that, due to its intrinsically
temporal nature, <italic toggle="yes">pseudotime</italic> can successfully extract aspects of the
underlying dynamics of a biological process from both bulk and single-cell datasets [<xref rid="ref15" ref-type="bibr">15–17</xref>].</p>
    <p>To the best of our knowledge, three fundamental aspects should be considered during the
inference of cancer drivers. Firstly, cancer evolves over time [<xref rid="ref18" ref-type="bibr">18</xref>, <xref rid="ref19" ref-type="bibr">19</xref>], therefore it is a
collection of dynamic processes and cancer drivers are actually driving one or more
processes during cancer progression. Secondly, genomic aberrations that drive cancer
progression are not limited to gene mutations [<xref rid="ref8" ref-type="bibr">8</xref>,
<xref rid="ref20" ref-type="bibr">20</xref>], so inference of cancer drivers based on gene
mutational burden lacks information from other essential aspects of cancer evolution.
Thirdly, under the definition of cancer driver as a gene that promotes the appearance and
progression of cancer, a driver gene is part of the causes of cancer development.
Consequently, the causal nature of the driver–cancer relationship should be considered
during the inference process. To overcome the limitations of current mutational and
network-based methods for cancer driver inference, while fulfilling the three fundamental
aspects discussed above, we have developed a <italic toggle="yes"><bold>dynamic cancer
drivers</bold></italic> inference approach.</p>
    <p>Our method takes gene expression data from cross-sectional studies, as well as a covariate
that reasonably modulates (in the sense described by Campbell and Yau [<xref rid="ref15" ref-type="bibr">15</xref>]) the <italic toggle="yes">pseudotemporal</italic> progression of one
relevant process occurring during cancer development. If no <italic toggle="yes">pseudotime</italic> is
provided, our method relies on <italic toggle="yes">PhenoPath</italic> [<xref rid="ref15" ref-type="bibr">15</xref>, <xref rid="ref21" ref-type="bibr">21</xref>] to find a
<italic toggle="yes">pseudotime</italic> score to order the samples following the trajectory encoded by
the covariate. We use the <italic toggle="yes">pseudotime</italic> (either provided or inferred by using
<italic toggle="yes">PhenoPath</italic>) and the covariate provided to find a critical turning point in
the trajectory along the <italic toggle="yes">pseudotime</italic>. We name this critical point as the
‘event’ (further discussion in Section <xref rid="sec2c" ref-type="sec">2.3</xref>). Please
note that in either case, our method requires a trajectory covariate.</p>
    <p>We hypothesize that the causal relationship between a driver gene and cancer development
induces a significant deviation (also referred as <italic toggle="yes">Causal Impact</italic>) of a core
process from normal to carcinogenic after the ‘event’. This <italic toggle="yes">Causal Impact</italic>
can be detected in the gene expression of such a driver gene. Thus, we assess the
<italic toggle="yes">Causal Impact</italic> of each ‘relevant’ gene after the ‘event’ (details in
Section <xref rid="sec2" ref-type="sec">2</xref>). If a gene expression reflects a
significant <italic toggle="yes">Causal Impact</italic> after the ‘event’, the corresponding gene is
considered as cancer driver for our method.</p>
    <p>We applied our <bold><italic toggle="yes">dynamic cancer drivers</italic></bold> approach to a
single-cell RNA sequencing dataset (NCBI GEO database, accession GSE75688) [<xref rid="ref22" ref-type="bibr">22</xref>], and <italic toggle="yes">the cancer genome atlas</italic>
breast cancer dataset (TCGA BRCA) [<xref rid="ref23" ref-type="bibr">23</xref>] (details in
Sections <xref rid="sec3a" ref-type="sec">3.1</xref> and <xref rid="sec3e" ref-type="sec">3.4</xref>, respectively). We assessed the ability of our method to expand current cancer
drivers catalogues, as well as its inference power. We used The Cancer Gene Census (CGC)
[<xref rid="ref24" ref-type="bibr">24</xref>] as a conservative approximation of the
ground truth since CGC catalogue is still in expansion, and thus non-CGC genes discovered by
our method should not be ruled out as drivers. Additionally, we used the TCGA–BRCA data to
compare our method with seven popular methods for cancer driver inference. The results show
our method outperforms them as it can discover more CGC genes, with better precision than
the other assessed methods.</p>
    <p>Our experiments suggest our method can identify driver genes for different trajectories
from the same dataset. Unlike other methods that can only identify a global (static) set of
cancer drivers, our method discovers <italic toggle="yes"><bold>dynamic drivers</bold></italic>, i.e
genes driving one or more core processes over cancer progression. Our results also suggest
that the temporal information not only improves performance of cancer drivers inference but
also allow us to identify genes driving specific processes along cancer development.</p>
  </sec>
  <sec id="sec2">
    <title>2 Methods</title>
    <sec id="sec2a">
      <title>2.1 Problem definition and method overview</title>
      <p>In our approach we name a <italic toggle="yes"><bold>dynamic cancer driver</bold></italic> as a gene
driving one (or more) significant biological processes along cancer progression. Under
this definition, our approach aims to elucidate cancer drivers by incorporating to the
inference process the dynamical information of the disease development. We consider the
following two aspects in our inference approach:</p>
      <list list-type="simple">
        <list-item>
          <p>(1) If a biological process is causing cancer to develop, in some point during its
progression there was a critical event that cause significant disturbances deviating
such a process from normal to carcinogenic. Although, in general a biological process
is not disruptive, we hypothesize there is a point along the process where transition
from normal to cancer becomes irreversible.</p>
        </list-item>
        <list-item>
          <p>(2) If a gene is driving a biological transition relevant for cancer to develop, it
should cause significant changes that can be detected on its own
<italic toggle="yes">pseudotime</italic> ordered gene expression (i.e. the
<italic toggle="yes">pseudotime</italic> series of the gene expression of the gene, Section <xref rid="sec2c1" ref-type="sec">2.3.1</xref>). We use abnormal gene expression as an
indicator of alterations in the behaviour of genes since the analysis of genes
differentially expressed as indicators of cancer is a common and widely accepted
approach.</p>
        </list-item>
      </list>
      <p>Dynamic information required for our causal inference of drivers will depend on the
process selected for study. Most of cancer datasets contain cross-sectional data, and thus
dynamic information is not explicitly available. We use a covariate encoding significant
aspects of the trajectory of interest, and <italic toggle="yes">pseudotime</italic> concept to extract
the underlying dynamics of such a process from cross-sectional datasets. We use the
framework <italic toggle="yes">PhenoPath</italic> provided by Campbell [<xref rid="ref15" ref-type="bibr">15</xref>, <xref rid="ref21" ref-type="bibr">21</xref>] for scoring each
sample to reflect its relative position along the biological process (or trajectory). We
selected <italic toggle="yes">PhenoPath</italic> framework for <italic toggle="yes">pseudotime</italic> scoring
because of its confirmed ability for extracting dynamical information from both
single-cell and bulk data [<xref rid="ref15" ref-type="bibr">15</xref>].</p>
      <p>Our method uses <italic toggle="yes">pseudotime score</italic> to order the samples. We denominate as
the <italic toggle="yes">pseudotime series</italic> of a gene <inline-formula><tex-math notation="LaTeX" id="ImEquation1">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$g$\end{document}</tex-math></inline-formula> to the
ordered gene expression in which an observation <inline-formula><tex-math notation="LaTeX" id="ImEquation2">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$g_t$\end{document}</tex-math></inline-formula> denotes the observation
at sample <inline-formula><tex-math notation="LaTeX" id="ImEquation3">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$t$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math notation="LaTeX" id="ImEquation4">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$t \in \{1,2,...,n\}$\end{document}</tex-math></inline-formula> indexes the samples in
<italic toggle="yes">pseudotime</italic> order (further discussion in Section <xref rid="sec2c" ref-type="sec">2.3</xref>). Our method can be summarized in three phases:</p>
      <list list-type="simple">
        <list-item>
          <p>(1) Network-based selection of putative drivers (Section <xref rid="sec2b" ref-type="sec">2.2</xref>): A specific <italic toggle="yes">Protein–Protein Interaction</italic>
(PPI) network is created from dataset. Most influential genes in this network are
labelled as putative cancer drivers.</p>
        </list-item>
        <list-item>
          <p>(2) Pseudotime series modelling and event detection (Section <xref rid="sec2c" ref-type="sec">2.3</xref>): A provided trajectory/path covariate and PPI genes in
dataset are used for <italic toggle="yes">pseudotime</italic> scoring. We use the term
<italic toggle="yes">pseudotime</italic> order to refer to the order of the samples that are
sorted in ascending order of the score. Scoring is performed by using the
<italic toggle="yes">PhenoPath pseudotime</italic> model proposed in [<xref rid="ref21" ref-type="bibr">21</xref>]. We used the calculated <italic toggle="yes">pseudotime</italic> score
for creating <italic toggle="yes">pseudotime series</italic> of both, genes and the path covariate.
We evaluate each sample following <italic toggle="yes">pseudotime</italic> order to detect the
‘event’.</p>
        </list-item>
        <list-item>
          <p>(3) Cancer drivers identification based of <italic toggle="yes">Causal Impact</italic> (Section
<xref rid="sec2f" ref-type="sec">2.4</xref>): We assess how significant the changes
on <italic toggle="yes">pseudotime series</italic> (after the ‘event’) are. Causal relationship
between genes and the selected process in cancer (encoded by the path covariate) is
assessed following a procedure inspired in the <italic toggle="yes">Causal Impact</italic> approach
proposed by Brodersen et al. [<xref rid="ref25" ref-type="bibr">25</xref>].</p>
        </list-item>
      </list>
    </sec>
    <sec id="sec2b">
      <title>2.2 Phase 1: Network-based selection of putative driver genes</title>
      <p>Starting with a matrix <inline-formula><tex-math notation="LaTeX" id="ImEquation5">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\textbf{G} \in \mathcal{R}^{n \times m}$\end{document}</tex-math></inline-formula>
containing the gene expression from <inline-formula><tex-math notation="LaTeX" id="ImEquation6">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$n$\end{document}</tex-math></inline-formula> samples and
<inline-formula><tex-math notation="LaTeX" id="ImEquation7">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$m$\end{document}</tex-math></inline-formula> genes, our method performs a dimensional
reduction <inline-formula><tex-math notation="LaTeX" id="ImEquation8">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\textbf{G}^{n \times m} \to \textbf{G}^{n \times k}$\end{document}</tex-math></inline-formula>,
with <inline-formula><tex-math notation="LaTeX" id="ImEquation9">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$k \le m$\end{document}</tex-math></inline-formula> by removing any gene not expressed
in at least 20% of the samples. We use the directed protein–protein interaction (PPI)
network provided by [<xref rid="ref26" ref-type="bibr">26</xref>] as input to classify the
remaining genes as ‘PPI genes’ or ‘non PPI genes’. This network consist on 34 814
gene–gene interactions from 6339 different genes. A data specific PPI network is created
from <inline-formula><tex-math notation="LaTeX" id="ImEquation10">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\textbf{G}$\end{document}</tex-math></inline-formula> as the PPI sub-network formed by
the genes present in the dimension reduced dataset (see Figure <xref rid="f2" ref-type="fig">2</xref>, item 1).</p>
      <fig position="float" id="f2">
        <label>Figure 2</label>
        <caption>
          <p>Summary of the proposed method for identifying genes driving relevant processes
making cancer to develop. (1) Starting with a gene expression dataset, our method
infers a dataset-specific Protein–Protein Interaction (PPI) network. Dataset is
divided in PPI and Non PPI genes. Genes with the most interactions in the specific PPI
network are considered putative drivers. (2) PPI genes and a trajectory covariate are
used for inferring a pseudotime order that follows the process of interest encoded by
the path covariate. Ordered samples are assessed to determine the most significant
change along the process, or critical event. All Gene expressions in the dataset are
ordered to create pseudotime series. (3) Pseudotime series of genes are used for
creating a counterfactual model. <italic toggle="yes">Causal Impact</italic> is calculated as the
differences between counterfactual and observed gene expression. If a significant
causal effect is detected, the gene is label as <bold><italic toggle="yes">dynamic cancer
driver</italic></bold>. If predicted and actual gene expression values are not
significantly different, the gene is labelled as non cancer driver.</p>
        </caption>
        <graphic xlink:href="elac030f2" position="float"/>
      </fig>
      <p>A gene is considered a <italic toggle="yes">putative driver</italic> for our method if such a gene:
(i) belongs to the data-specific PPI network inferred and (ii) the degree of its
corresponding node (degree defined as the total of interactions of the gene in the
inferred PPI network) is part of the top 40% of the degree of nodes distribution. Although
this parameter can be adapted, our experiments show a suitable threshold stays between top
50% and top 25%.</p>
    </sec>
    <sec id="sec2c">
      <title>2.3 Phase 2: Pseudotime series modelling and event detection</title>
      <sec id="sec2c1">
        <title>2.3.1 Pseudotime series</title>
        <p>As we have assumed cancer progression is a compendium of heterogeneous processes, there
are several relevant trajectories that can be employed for our dynamic causal inference
of cancer drivers. The definition of a process of interest is fulfilled by using a
provided trajectory covariate <inline-formula><tex-math notation="LaTeX" id="ImEquation11">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$P$\end{document}</tex-math></inline-formula>. It is assumed that
the provided covariate <inline-formula><tex-math notation="LaTeX" id="ImEquation12">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$P$\end{document}</tex-math></inline-formula> encodes significant aspects of the
latent progression of the samples (e.g. patients, tumours, cells, etc). Assumption of
existence of such a covariate is reasonable as <italic toggle="yes">pseudotime</italic> order usually
reflects progression associated with prior factors of interest [<xref rid="ref15" ref-type="bibr">15</xref>]. In general, a numeric vector (e.g. gene expression of a
biomarker) or categorical values (such as oestrogen-receptor (ER) status in breast
cancer) can be used as a suitable covariate.</p>
        <p>Formally, given an expression matrix of all ‘PPI genes’ in the dataset-specific PPI
network (obtained in phase 1, see Figure <xref rid="f2" ref-type="fig">2</xref>) and a
path covariate <inline-formula><tex-math notation="LaTeX" id="ImEquation13">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$P$\end{document}</tex-math></inline-formula>, our method utilizes
<italic toggle="yes">pseudotime</italic> concept to score each sample to reflect its relative
position along such a process. In this paper, <inline-formula><tex-math notation="LaTeX" id="ImEquation14">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$P$\end{document}</tex-math></inline-formula> is considered to be a
numerical (continuous) covariate. In order to be valid, selected covariate must have a
unique value matching each sample in the dataset. If no <italic toggle="yes">pseudotime</italic>
order is provided, our method relies on <italic toggle="yes">PhenoPath</italic> [<xref rid="ref21" ref-type="bibr">21</xref>] for scoring each sample. The dataset samples are reordered
in <italic toggle="yes">pseudotime</italic> order. Consequently, each column in the dataset now is
considered a <italic toggle="yes">pseudotime series</italic> (Figure <xref rid="f2" ref-type="fig">2</xref>, item 2).</p>
      </sec>
      <sec id="sec2c2">
        <title>2.3.2 Event detection</title>
        <p>To detect the critical event (or event for short), we test the <italic toggle="yes">pseudotime
series</italic> of the path covariate to determine the sample at which the most
significant change happens (i.e. the ‘event’). Our method orders the path covariate
<inline-formula><tex-math notation="LaTeX" id="ImEquation15">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$P$\end{document}</tex-math></inline-formula> by using the
<italic toggle="yes">pseudotime</italic> score (as explained in Section <xref rid="sec2c1" ref-type="sec">2.3.1</xref>) to create its <italic toggle="yes">pseudotime series</italic>. It is
assumed the ‘event’ is not in the first five or last five samples (in
<italic toggle="yes">pseudotime</italic> order). This restriction is made based on the assumption
that the provided dataset contains samples reasonably dispersed along the trajectory.
This requirement may not be fulfilled when using a dataset including only samples on a
very limited region of the transition, and thus not reflecting adequately the
progression of the biological process.</p>
        <p>For the event detection, we used a modified version of <italic toggle="yes">Causal Impact</italic>
[<xref rid="ref25" ref-type="bibr">25</xref>] in our approach. To assess whether
changes in a response variable are due to a treatment <italic toggle="yes">Causal Impact</italic>
requires a time series of the response variable and a contemporaneous time series that
is unaffected by the treatment. <italic toggle="yes">Causal Impact</italic> uses the unaffected time
series as reference level for counterfactual estimations.</p>
        <p>In our approach, we utilize the path covariate P as a proxy of a response variable as
we expect that its pseudotime series encodes the changes due to cancer of a biological
process of interest. Changes in a dynamic cancer driver are expected to be similar to
the changes encoded by the path covariate. For such a reason, and because our putative
drivers belong to the PPI network, we have ruled out ‘PPI genes’ as suitable references
for the counterfactual estimations required by <italic toggle="yes">Causal Impact</italic>, and we
only use ‘non PPI’ genes as the references. The ‘event’ identification is performed as
follows:</p>
        <list list-type="simple">
          <list-item>
            <p><bold>(a)</bold> Find the ‘non PPI’ gene with the largest <italic toggle="yes">Pearson</italic>
correlation with the path covariate <inline-formula><tex-math notation="LaTeX" id="ImEquation16">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$P$\end{document}</tex-math></inline-formula>.</p>
          </list-item>
          <list-item>
            <p><bold>(b)</bold> Starting from the 5th sample (in <italic toggle="yes">pseudotime</italic>
order), set current sample as ‘plausible event’.</p>
          </list-item>
          <list-item>
            <p><bold>(c)</bold> Use data from all samples before current ‘plausible event’ (i.e.
from sample 1 to current ‘plausible event’) to fit a regression model as shown in
equation <xref rid="deqn01" ref-type="disp-formula">1</xref>  <disp-formula id="deqn01"><label>(1)</label><tex-math notation="LaTeX" id="DmEquation1">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{align*}&amp; \hat{P}_t = \mu_t + \delta_t + \beta \hat{x}_t+\varepsilon_t \;\;\; \text{ with} \;\;\; \varepsilon_t \sim \mathcal{N}(0,\sigma_t^2), \end{align*}\end{document}</tex-math></disp-formula>where
<inline-formula><tex-math notation="LaTeX" id="ImEquation17">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\hat{P}_t$\end{document}</tex-math></inline-formula> is the predicted value of
<inline-formula><tex-math notation="LaTeX" id="ImEquation18">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$P$\end{document}</tex-math></inline-formula> at <italic toggle="yes">pseudotime</italic>
 <inline-formula><tex-math notation="LaTeX" id="ImEquation19">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$t$\end{document}</tex-math></inline-formula>, and <inline-formula><tex-math notation="LaTeX" id="ImEquation20">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\hat{x}_t$\end{document}</tex-math></inline-formula> is the value at
<inline-formula><tex-math notation="LaTeX" id="ImEquation21">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$t$\end{document}</tex-math></inline-formula> of the <italic toggle="yes">pseudotime
series</italic> of the ‘non PPI gene’ selected in step <bold>a</bold>,
<inline-formula><tex-math notation="LaTeX" id="ImEquation22">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\mu _t$\end{document}</tex-math></inline-formula> is the current local linear
trend level and <inline-formula><tex-math notation="LaTeX" id="ImEquation23">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\delta _t$\end{document}</tex-math></inline-formula> its respective slope,
<inline-formula><tex-math notation="LaTeX" id="ImEquation24">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\beta $\end{document}</tex-math></inline-formula> is a regression coefficient,
and <inline-formula><tex-math notation="LaTeX" id="ImEquation25">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\varepsilon _t$\end{document}</tex-math></inline-formula> is the error term.</p>
          </list-item>
          <list-item>
            <p><bold>(d)</bold> Use model obtained in <bold>c</bold> to get predicted values of
<inline-formula><tex-math notation="LaTeX" id="ImEquation26">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$P$\end{document}</tex-math></inline-formula> for all samples from current
‘plausible event’ on.</p>
          </list-item>
          <list-item>
            <p><bold>(e)</bold> Check whether differences between predicted and observed values are
significant, and assess if those differences are due to cancer. This is done by
retrieving the <italic toggle="yes">Relative Causal Impact</italic> for each ‘plausible event’,
calculated as shown in equation <xref rid="deqn02" ref-type="disp-formula">2</xref>
(a detailed explanation of <italic toggle="yes">Causal Impact</italic> in our method is presented
in <xref rid="sec2f" ref-type="sec">2.4</xref>). <disp-formula id="deqn02"><label>(2)</label><tex-math notation="LaTeX" id="DmEquation2">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{align*}&amp; \text{Relative Causal Impact} = \frac{\sum_{\text{post-period}}{P_t}}{\sum_{\text{post-period}}{\hat{P}_t}} - 1 , \end{align*}\end{document}</tex-math></disp-formula>where
post-period refers to <italic toggle="yes">pseudotime</italic> values from current plausible
event on, <inline-formula><tex-math notation="LaTeX" id="ImEquation27">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$P_t$\end{document}</tex-math></inline-formula> is actual value of
<inline-formula><tex-math notation="LaTeX" id="ImEquation28">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$P$\end{document}</tex-math></inline-formula> at <italic toggle="yes">pseudotime</italic>
 <inline-formula><tex-math notation="LaTeX" id="ImEquation29">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$t$\end{document}</tex-math></inline-formula>, and <inline-formula><tex-math notation="LaTeX" id="ImEquation30">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\hat{P}_t$\end{document}</tex-math></inline-formula> is the contemporaneous
predicted value.</p>
          </list-item>
          <list-item>
            <p><bold>(f)</bold> Label the ‘plausible event’ with the largest (significant)
<italic toggle="yes">Relative Causal Impact</italic> as the identified ‘event’.</p>
          </list-item>
        </list>
      </sec>
    </sec>
    <sec id="sec2f">
      <title>2.4 Phase 3: Cancer drivers identification based on Causal Impact</title>
      <p>Given a causal relationship of two variables A <inline-formula><tex-math notation="LaTeX" id="ImEquation31">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\rightarrow $\end{document}</tex-math></inline-formula> B (read as A
causes B) ongoing from an arbitrary time <inline-formula><tex-math notation="LaTeX" id="ImEquation32">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$t_e$\end{document}</tex-math></inline-formula>, the <italic toggle="yes">Causal
Impact</italic> of B (the response variable) due to A (the cause) is described as the
potential change (after time <inline-formula><tex-math notation="LaTeX" id="ImEquation33">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$t_e$\end{document}</tex-math></inline-formula>) of B induced by A. In other words, the
<italic toggle="yes">Causal Impact</italic> on B is the difference between observed values of B after
<inline-formula><tex-math notation="LaTeX" id="ImEquation34">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$t_e$\end{document}</tex-math></inline-formula> and the value that B would have had if
A would have not existed [<xref rid="ref25" ref-type="bibr">25</xref>].</p>
      <p>In our approach it is assumed that the causal effect of a driver in the biological
process is reflected on the <italic toggle="yes">pseudotime series</italic> of such a driver.
Consequently, we defined the <italic toggle="yes">Causal Impact</italic> of a driver gene as the
difference between values due to cancer of the (observed) gene expression of such a gene,
and the (unobserved) gene expression of the same gene if cancer would have not occurred.
In our setting, we define <inline-formula><tex-math notation="LaTeX" id="ImEquation35">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$t_e$\end{document}</tex-math></inline-formula> as the index of the sample (in
<italic toggle="yes">pseudotime</italic> order) where the most critical change occurred (i.e. the
‘event’). Furthermore, response variables in our approach are <italic toggle="yes">pseudotime
series</italic> of putative drivers (Section <xref rid="sec2b" ref-type="sec">2.2</xref>). Identification of the ‘event’ <inline-formula><tex-math notation="LaTeX" id="ImEquation36">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$t_e$\end{document}</tex-math></inline-formula> is made as explained
in Section <xref rid="sec2c2" ref-type="sec">2.3.2</xref>.</p>
      <p>In order to obtain the unobserved gene expression of a putative driver a counterfactual
model of the respective <italic toggle="yes">pseudotime series</italic> is required. Such a
counterfactual model can be achieved by using another <italic toggle="yes">pseudotime series</italic>
as contemporaneous covariate to tune a regression model [<xref rid="ref27" ref-type="bibr">27</xref>]. We select as covariate for a putative driver the ‘non PPI gene’ with the
largest <italic toggle="yes">Pearson</italic> correlation with such a putative driver. We select
covariates from the group of ‘non PPI genes’ as they are outside the PPI network and we
hypothesize that changes in ‘PPI genes’ after the ‘event’ do not induce changes in the
covariates.</p>
      <p>The process for obtaining counterfactual estimations of a putative cancer driver is as
follows: (i) determine the sample representing the most significant change along the path
of interest, or ‘event’ (as shown in Section <xref rid="sec2c2" ref-type="sec">2.3.2</xref>), (ii) find a counterfactual model of the putative driver using its data
before the ‘event’ (Section <xref rid="sec2f1" ref-type="sec">2.4.1</xref>) and (iii) use
the model from (ii) to obtain counterfactual data after the ‘event’.</p>
      <sec id="sec2f1">
        <title>2.4.1 Counterfactual Model</title>
        <p>A state space representation of time series data is used as counterfactual model to
estimate <italic toggle="yes">pseudotime series</italic> of putative drivers if cancer were not
happened. State space representation is a widely accepted approach for modelling time
series and dynamic systems. It relates observed values of variables in a system with
latent states of such variables (please see [<xref rid="ref28" ref-type="bibr">28</xref>] for a comprehensive explanation).</p>
        <p>In this paper, given the expression profile of a putative driver gene
<inline-formula><tex-math notation="LaTeX" id="ImEquation37">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$g \in \textbf{G}$\end{document}</tex-math></inline-formula>, its corresponding
<italic toggle="yes">pseudotime series</italic> is modelled using the state space model described
in equations <xref rid="deqn03" ref-type="disp-formula">3</xref> and <xref rid="deqn04" ref-type="disp-formula">4</xref>. Data before the ‘event’ (in <italic toggle="yes">pseudotime
order</italic>) are used to fit the state space model. The model is used for obtaining
counterfactual estimations (from the ‘event’ on). Specifically, we used the adapted
version of [<xref rid="ref29" ref-type="bibr">29</xref>] state representation model
[<xref rid="ref25" ref-type="bibr">25</xref>, <xref rid="ref29" ref-type="bibr">29</xref>, <xref rid="ref30" ref-type="bibr">30</xref>] as shown below: <disp-formula id="deqn03"><label>(3)</label><tex-math notation="LaTeX" id="DmEquation3">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{align*} {g}_t = Z_t^T\alpha_t +\varepsilon_t \;\;\; \text{ with} \;\;\; \varepsilon_t \sim \mathcal{N}(0,\sigma_t^2), \end{align*}\end{document}</tex-math></disp-formula>
 <disp-formula id="deqn04"><label>(4)</label><tex-math notation="LaTeX" id="DmEquation4">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{align*} \alpha_{t+1}=T_t\alpha_t+R_t\eta_t \;\;\; \text{ with} \;\;\; \eta_t \sim \mathcal{N}(0,Q_t), \end{align*}\end{document}</tex-math></disp-formula>where
equation <xref rid="deqn03" ref-type="disp-formula">3</xref> is known as the
<italic toggle="yes">observation</italic> equation and it relates <inline-formula><tex-math notation="LaTeX" id="ImEquation38">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$g_t$\end{document}</tex-math></inline-formula> (an
observed value of the <italic toggle="yes">pseudotime series</italic> of gene
<inline-formula><tex-math notation="LaTeX" id="ImEquation39">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$g$\end{document}</tex-math></inline-formula>) with the vector of latent states
<inline-formula><tex-math notation="LaTeX" id="ImEquation40">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\alpha _t = [\mu _t \;\; \delta _t \;\; 1]^T$\end{document}</tex-math></inline-formula>
through the <italic toggle="yes">output vector</italic>  <inline-formula><tex-math notation="LaTeX" id="ImEquation41">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$Z_t^T = [1 \;\;1\;\; \beta x_t]$\end{document}</tex-math></inline-formula>.</p>
        <p>In this model, <inline-formula><tex-math notation="LaTeX" id="ImEquation42">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\mu _t$\end{document}</tex-math></inline-formula> is the current local linear trend
level and <inline-formula><tex-math notation="LaTeX" id="ImEquation43">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\delta _t$\end{document}</tex-math></inline-formula> its respective slope,
<inline-formula><tex-math notation="LaTeX" id="ImEquation44">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$x_t$\end{document}</tex-math></inline-formula> (used as covariate) is the
contemporary value of the ‘non PPI gene’ with the largest <italic toggle="yes">Pearson</italic>
correlation with <inline-formula><tex-math notation="LaTeX" id="ImEquation45">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$g$\end{document}</tex-math></inline-formula>, <inline-formula><tex-math notation="LaTeX" id="ImEquation46">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\beta $\end{document}</tex-math></inline-formula>
is a regression coefficient and the <inline-formula><tex-math notation="LaTeX" id="ImEquation47">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\varepsilon _t$\end{document}</tex-math></inline-formula> term is
an scalar observation error following a normal distribution <inline-formula><tex-math notation="LaTeX" id="ImEquation48">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\mathcal{N}(0,\sigma _t^2)$\end{document}</tex-math></inline-formula>. Equation
<xref rid="deqn04" ref-type="disp-formula">4</xref> is the <italic toggle="yes">transition</italic>
equation and it describes the evolution of the latent states (<inline-formula><tex-math notation="LaTeX" id="ImEquation49">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\alpha _t$\end{document}</tex-math></inline-formula>) over time. Here,
<inline-formula><tex-math notation="LaTeX" id="ImEquation50">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$T_t$\end{document}</tex-math></inline-formula> is a squared transition matrix, and
<inline-formula><tex-math notation="LaTeX" id="ImEquation51">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$R_t\eta _t$\end{document}</tex-math></inline-formula> is the error term.</p>
        <p>Counterfactual estimations <inline-formula><tex-math notation="LaTeX" id="ImEquation52">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\hat{g}_t$\end{document}</tex-math></inline-formula> are achieved by evaluating
equations <xref rid="deqn03" ref-type="disp-formula">3</xref> and <xref rid="deqn04" ref-type="disp-formula">4</xref> for all <inline-formula><tex-math notation="LaTeX" id="ImEquation53">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$t \ge t_e$\end{document}</tex-math></inline-formula> (from the
‘event’ on). These estimations are used to calculate the <italic toggle="yes">Causal Impact</italic>
reflected in the <italic toggle="yes">pseudotime series</italic> of the putative driver (equation
<xref rid="deqn05" ref-type="disp-formula">5</xref>). <disp-formula id="deqn05"><label>(5)</label><!-- edit 1 --><mml:math id="M1" display="block" overflow="scroll"><mml:mtable columnalign="right left right left right left right left right left right left" rowspacing="3pt" columnspacing="0em 2em 0em 2em 0em 2em 0em 2em 0em 2em 0em" displaystyle="true"><mml:mtr><mml:mtd/><mml:mtd><mml:msub><mml:mtext>Causal_Impact</mml:mtext><mml:mi>t</mml:mi></mml:msub><mml:mo>:=</mml:mo><mml:msub><mml:mi>g</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>−<!-- &#x02212; --></mml:mo><mml:msub><mml:mrow class="MJX-TeXAtom-ORD"><mml:mover><mml:mi>g</mml:mi><mml:mo stretchy="false">^<!-- ^ --></mml:mo></mml:mover></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:mspace width="thickmathspace"/><mml:mspace width="thickmathspace"/><mml:mspace width="thickmathspace"/><mml:mspace width="thickmathspace"/><mml:mspace width="thickmathspace"/><mml:mspace width="thickmathspace"/><mml:mi mathvariant="normal">∀<!-- &#x02200; --></mml:mi><mml:mspace width="thickmathspace"/><mml:mspace width="thickmathspace"/><mml:mspace width="thickmathspace"/><mml:msub><mml:mi>t</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>≤<!-- &#x02264; --></mml:mo><mml:mi>t</mml:mi><mml:mo>≤<!-- &#x02264; --></mml:mo><mml:mi>n</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p>
        <p>Counterfactual modelling in our method and evaluation of the significance of the
<italic toggle="yes">Causal Impact</italic> are performed by using the
<italic toggle="yes">CausalImpact</italic> function from the <italic toggle="yes">Causal Impact</italic> R
package [<xref rid="ref25" ref-type="bibr">25</xref>].</p>
      </sec>
      <sec id="sec2f2">
        <title>2.4.2 Dynamic cancer drivers discovery</title>
        <p>In this step, putative drivers with a significant <italic toggle="yes">Causal Impact</italic>
detected from its own <italic toggle="yes">pseudotime</italic> series are considered
<bold><italic toggle="yes">dynamic cancer drivers</italic></bold> (Figure <xref rid="f2" ref-type="fig">2</xref>, item 3). We consider there is a significant <italic toggle="yes">Causal
Impact</italic> of a putative driver if the causal effect calculated by using observed
and predicted gene expression values after <inline-formula><tex-math notation="LaTeX" id="ImEquation54">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$t_e$\end{document}</tex-math></inline-formula> (the ‘event’) is
statistically significant (<italic toggle="yes">CausalImpact P</italic>-value
<inline-formula><tex-math notation="LaTeX" id="ImEquation55">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$&lt; 0.05$\end{document}</tex-math></inline-formula>).</p>
      </sec>
    </sec>
  </sec>
  <sec id="sec3">
    <title>3 Results</title>
    <sec id="sec3a">
      <title>3.1 Dynamic cancer drivers identified from single-cell data</title>
      <p>We applied our method to the single-cell RNA sequencing data from NCBI GEO database,
accession GSE75688 [<xref rid="ref22" ref-type="bibr">22</xref>]. This dataset contains
gene expression from 11 breast cancer patients (515 single-cell sequencing data) with
distinct molecular subtypes: oestrogen receptor positive (ER+), double positive (ER+ and
HER2+), human epidermal growth factor receptor 2 positive (HER2+) and triple-negative
breast cancer (TNBC). We performed our inference by using 317 out of 515 cells from this
dataset, corresponding to all tumour cells provided. The dataset after removing low
expressed genes has the gene expression of 9551 genes.</p>
      <p>Samples were ordered following two different <italic toggle="yes">pseudotimes</italic> calculated by
using HER2 and VIM expressions as path covariates, respectively. HER2 was employed as
trajectory covariate for generic breast cancer progression as it is a well-recognized
oncogene whose disregulation influences breast cancer development. Similarly, VIM was used
as trajectory covariate of the <italic toggle="yes">Epithelial to Mesenchymal</italic>
(<italic toggle="yes">EMT</italic>) process because of the fact that VIM is a well-recognized
<italic toggle="yes">EMT marker</italic>. As a result, our method identified two sets of drivers, one
from each pseudotime order. For simplicity, we refer these pseudotime orders as
‘HER2time(SC)’ and ‘VIMtime(SC)’ from now on.</p>
      <p>A total of 604 genes were inferred as drivers during generic breast cancer progression
(as encoded by ‘HER2time(SC)’), while a total of 545 genes were inferred to drive
<italic toggle="yes">EMT</italic> following ‘VIMtime(SC)’ from this dataset (please refer to Table
<xref rid="TB1" ref-type="table">1</xref>). Our method is able to identify 98 and 93
experimentally confirmed cancer drivers listed by the <italic toggle="yes">Cancer Gene Census</italic>
(v94, n = 719) [<xref rid="ref24" ref-type="bibr">24</xref>] (also called CGC genes) from
‘HER2time(SC)’ and ‘VIMtime(SC)’, respectively. For further analysis, we combined our
discoveries in one single list, resulting in 934 inferred genes. Among them, a total of
155 CGC genes were identified (Table <xref rid="TB1" ref-type="table">1</xref>).</p>
      <table-wrap position="float" id="TB1">
        <label>Table 1</label>
        <caption>
          <p>Summary of Inferred Drivers: Size of the different sets of drivers inferred from each
pseudotime. Combined shows number of the union set</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col span="2" align="left"/>
            <col span="3" align="left"/>
            <col span="4" align="left"/>
          </colgroup>
          <thead>
            <tr>
              <th rowspan="1" colspan="1"/>
              <th rowspan="1" colspan="1">HER2time(SC)</th>
              <th rowspan="1" colspan="1">VIMtime(SC)</th>
              <th rowspan="1" colspan="1">Combined(SC)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Total inferred</td>
              <td rowspan="1" colspan="1">604</td>
              <td rowspan="1" colspan="1">545</td>
              <td rowspan="1" colspan="1">934</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CGC genes</td>
              <td rowspan="1" colspan="1">98</td>
              <td rowspan="1" colspan="1">93</td>
              <td rowspan="1" colspan="1">155</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">% of CGC genes</td>
              <td rowspan="1" colspan="1">16.225</td>
              <td rowspan="1" colspan="1">17.064</td>
              <td rowspan="1" colspan="1">16.595</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>As expected, different set of genes are identified as drivers of each biological
transition of interest from our experiments. The 545 <italic toggle="yes"><bold>dynamic cancer
drivers</bold></italic> inferred following <italic toggle="yes">EMT</italic> as encoded by
‘VIMtime(SC)’ and the 604 inferred from ‘HER2time(SC)’ are distributed as follows: 36 CGC
genes detected as drivers in both trajectories, 57 CGC genes detected by following
(exclusively) ‘VIMtime(SC)’, 62 CGC genes driving cancer progression following
(exclusively) ‘HER2time(SC)’, 179 non-CGC genes detected in both trajectories, 273 non-CGC
genes detected from ‘VIMtime(SC)’ and 327 non-CGC genes detected from ‘HER2time(SC)’
(please see Figure <xref rid="f3" ref-type="fig">3</xref>). <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Supplementary table 1</xref></italic> and
<italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Supplementary table
2</xref></italic> (in <italic toggle="yes">supplementary material</italic>) show the top 100
<italic toggle="yes"><bold>dynamic cancer drivers</bold></italic> from ‘HER2time(SC)’ and
‘VIMtime(SC)’, ranked by Relative Causal Impact (descending order), respectively. The full
list of drivers inferred from the single-cell data set employed can be found at <ext-link xlink:href="https://github.com/AndresMCB/DynamicCancerDriver" ext-link-type="uri">https://github.com/AndresMCB/DynamicCancerDriver</ext-link>.</p>
      <fig position="float" id="f3">
        <label>Figure 3</label>
        <caption>
          <p>Chow–Ruskey Venn diagram of our discoveries when exploring drivers following
VIMtime(SC) and HER2time(SC) order. The 155 CGC genes detected by our method
correspond to 57 discovered from VIMtime(SC), 62 discovered from HER2time(SC) and 36
detected in both trajectories. Novel inferred drivers are distributed as follows: 273
inferred by following ‘VIMtime(SC)’, 327 inferred by following ‘HER2time(SC)’ and 179
genes inferred to drive both trajectories. Figure made using intervene [<xref rid="ref31" ref-type="bibr">31</xref>] (<ext-link xlink:href="https://intervene.shinyapps.io/intervene/" ext-link-type="uri">https://intervene.shinyapps.io/intervene/</ext-link>).</p>
        </caption>
        <graphic xlink:href="elac030f3" position="float"/>
      </fig>
    </sec>
    <sec id="sec3b">
      <title>3.2 Our method contributes to expanding current cancer drivers catalogues</title>
      <p>We adapted the metric described in Dietlein et al. [<xref rid="ref2" ref-type="bibr">2</xref>] to assess the ability of our method to contribute to the expansion of current
cancer drivers catalogues. We examined the 155 CGC genes discovered as drivers from our
method (union set of ‘VIMtime(SC)’ and ‘HER2time(SC)’ inferences) and compared them with
CGC genes reported in previous (comprehensive) studies for driver-gene discovery. Under
this approach, the ability of our method to expand previous catalogues is correlated with
the number of additional CGC genes the method discovered. Additional CGC genes are genes
in CGC that are inferred by our method but not present in any of the catalogues. A brief
description of studies selected for this assessment is shown below.</p>
      <p>We selected six comprehensive studies providing catalogues of highly confident drivers.
Lawrence et al. provide a catalogue of driver genes obtained from 4742 tumour data by
using the MutSigCV suite [<xref rid="ref32" ref-type="bibr">32</xref>]. Martincorena et
al. [<xref rid="ref33" ref-type="bibr">33</xref>] used the dNdScv algorithm on 7664
tumours to assemble a cancer drivers list. Bailey et al. [<xref rid="ref4" ref-type="bibr">4</xref>] create a catalogue by applying a combination of 26 different computational
tools for driver genes inference to 9423 tumours. Priestley et al. [<xref rid="ref34" ref-type="bibr">34</xref>] provide a driver mutation catalogue discovered from 2520
paired tumour and normal genomes from 2399 patients. Dietlein et al. [<xref rid="ref2" ref-type="bibr">2</xref>] identified drivers from 11 873 tumour-normal pairs by using a
novel method (MutPanning) based on nucleotide context. Finally, Rheinbay et al. [<xref rid="ref35" ref-type="bibr">35</xref>] provide a catalogue of coding and non-coding
cancer drivers inferred by analysing 2658 genomes from the Pan-Cancer Analysis of Whole
Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The
Cancer Genome Atlas (TCGA) [<xref rid="ref36" ref-type="bibr">36</xref>].</p>
      <p>From the 155 CGC genes identified by our method, 53 are not part of any of the
aforementioned catalogues. Similarly, we count the number of additional CGC genes that can
be found in each catalogue (i.e CGC genes that are not in any other of the studies). The
number of additional CGC genes from each catalogue are as follows: [<xref rid="ref34" ref-type="bibr">34</xref>] 51; [<xref rid="ref2" ref-type="bibr">2</xref>] 25, [<xref rid="ref4" ref-type="bibr">4</xref>] 12, [<xref rid="ref35" ref-type="bibr">35</xref>]
4, [<xref rid="ref32" ref-type="bibr">32</xref>] 2 and [<xref rid="ref33" ref-type="bibr">33</xref>] 0 (please refer to Figure <xref rid="f4" ref-type="fig">4</xref>). The above
suggests that the ability of our method to detect additional drivers is useful for
expanding previous studies findings.</p>
      <fig position="float" id="f4">
        <label>Figure 4</label>
        <caption>
          <p>Comparative of number of novel CGC genes inferred by our method and novel CGC of each
of the cancer drivers catalogues analysed. A CGC gene is considered novel for our
method if such a gene does not belong to any of the analysed catalogues. Similarly, a
CGC gene in a catalogue is considered novel is such a gene is not present in any other
of the catalogues. Our method is capable to detect 53 novel CGC, suggesting our method
is useful for expanding current comprehensive catalogues.</p>
        </caption>
        <graphic xlink:href="elac030f4" position="float"/>
      </fig>
      <sec id="sec3b1">
        <title>3.2.1 Stratification of inferred driver genes based on literature support</title>
        <p>To further explore the idea of contributing to the expansion of current cancer drivers
catalogues, we have assembled a stratified list of <italic toggle="yes"><bold>dynamic cancer
drivers</bold></italic>. In our proposed catalogue we only consider the 215 genes
discovered as drivers in the intersection of both <italic toggle="yes">pseudotime</italic> orders
(179 novel genes and 36 CGC genes, see Figure <xref rid="f3" ref-type="fig">3</xref>) as
they are relevant to both of the trajectories analysed.</p>
        <p>Stratification corresponds to level of confidence as driver gene. We have classified
the 215 inferred genes in the following four categories: <bold>A</bold>—the gene is a
CGC gene, <bold>B</bold>—the gene has literature support as influential for breast
cancer, <bold>C</bold>—the gene have literature support as influential for other cancer
but breast cancer and <bold>D</bold>—there is not literature describing the gene as
influential for cancer. Inclusion criteria for the literature review were: (i) paper
explicitly refers the gene has a significant role in cancer, (ii) publication dated 2016
onwards and (iii) study is published in a journal with impact factor 5.1 or higher (as
shown in <italic toggle="yes">web of knowledge</italic>, website visited in August 2021).</p>
        <p>Among the 215 classified genes, 36 are CGC genes (A), 57 genes have been related to
breast cancer (B), 69 genes have literature support regarding other cancer (C) and 53
genes have no literature support yet. For example, the receptor tyrosine kinase AXL,
inferred for our method as the gene with the largest <italic toggle="yes">Relative Causal
Impact</italic>, has been found to stimulate the phosphorylation of a network of focal
adhesion (FA) proteins, promoting metastasis in breast cancer cells [<xref rid="ref37" ref-type="bibr">37</xref>]. The same gene has been considered as a potential target
for cancer therapy since its knockdown is related to slower growth and increased
radiosensitivity in breast cancer tumours [<xref rid="ref38" ref-type="bibr">38</xref>].
We use the <italic toggle="yes">Relative Causal Impact</italic> for ranking our discoveries as it is
the percentual version of <italic toggle="yes">Causal Impact</italic>, and thus eliminates the bias
towards highly expressed genes.</p>
        <p>Genes in the top 10 of inferred drivers (ranked by <italic toggle="yes">Relative Causal
Impact</italic>) are distributed as follows: one gene has been found to be a confirmed
cancer driver (IRF4 ranked in top two), six genes have support from experimental studies
(AXL, IGF1R, STC2, MBD3, SATB1, ENO2) and three genes has no literature support yet.
IGF1R (our top five) has been found to co-regulate tumourigenes and cancer progression
in breast cancer [<xref rid="ref39" ref-type="bibr">39</xref>]. STC2 (top three)
promotes <italic toggle="yes">EMT</italic> progression in colorectal cancer, inducing tumourigenesis
[<xref rid="ref40" ref-type="bibr">40</xref>]. MBD3 (top four) plays a significant
role in <italic toggle="yes">EMT</italic> process and tumour metastasis [<xref rid="ref41" ref-type="bibr">41</xref>]. SATB1 (top seven) plays a critical role in relevant
pathways conferring anti-tumour immunity [<xref rid="ref42" ref-type="bibr">42</xref>].
Lastly, knockdown of ENO2 (top nine) has been associated with a reduction on the
survival rate of leukaemia cells [<xref rid="ref43" ref-type="bibr">43</xref>]. The full
stratified list can be found in <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Supplementary table 3</xref></italic>. The full list with references from
our literature review can be found in the <italic toggle="yes">Supplementary</italic> folder at
<ext-link xlink:href="https://github.com/AndresMCB/DynamicCancerDriver" ext-link-type="uri">https://github.com/AndresMCB/DynamicCancerDriver</ext-link>.</p>
      </sec>
    </sec>
    <sec id="sec3d">
      <title>3.3 Dynamic cancer drivers inferred from single-cell data are significantly related
to cancer disease</title>
      <p>We performed an enrichment analysis (GO biological processes 2021) to verify how
significantly related are our discoveries to processes in cancer. Additionally, we
explored gene–disease associations (GDAs) among our inferred drivers by checking the
overlap between our inferred genes and the human GDAs provided by DisGeNET [<xref rid="ref44" ref-type="bibr">44</xref>].</p>
      <p>Our analyses show a significant number of discovered drivers are strongly related to
cancer disease. The top five GO Biological Processes and the top five GDAs enriched terms
for VIMtime(SC) (ranked by <italic toggle="yes">P</italic>-value) are shown in Table <xref rid="TB2" ref-type="table">2</xref>. The top 10 enriched terms for each of our
enrichment analyses are provided in <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Supplementary table 4</xref></italic> (GO terms HER2time(SC)),
<italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Supplementary table
5</xref></italic> (GO terms VIMtime(SC)), <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Supplementary table 6</xref></italic>
(GDAs HER2Time(SC)) and <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Supplementary table 7</xref></italic> (GDAs VIMtime(SC)). An extended visual
representation (top 10) for both GO terms and GDAs terms can be found in <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">supplementary material (Figures 1,
2)</xref></italic>. The full outcome of our analyses (including the list of enriched
genes) can be found at <ext-link xlink:href="https://github.com/AndresMCB/DynamicCancerDriver" ext-link-type="uri">https://github.com/AndresMCB/DynamicCancerDriver</ext-link>. Drivers discovered by
following <italic toggle="yes">EMT</italic> process are in general related to generic processes in
cancer (e.g cancinogenesis in top one and neoplasm metastasis in top five of DGAs), while
drivers inferred following ‘HER2time(SC)’ are more closely related to breast cancer.</p>
      <table-wrap position="float" id="TB2">
        <label>Table 2</label>
        <caption>
          <p>Top five of GO Biological Processes (left) and DisGeNET DGAs (right) enriched terms
among drivers inferred from VIMtime(SC)</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col span="2" align="left"/>
            <col span="3" align="left"/>
            <col span="4" align="left"/>
            <col span="5" align="left"/>
          </colgroup>
          <thead>
            <tr>
              <th rowspan="1" colspan="1">
                <bold>GO Biological Process Term</bold>
              </th>
              <th rowspan="1" colspan="1">
                <bold>P-value</bold>
              </th>
              <th rowspan="1" colspan="1">
                <bold>Disease–Gene Association Term (DisGeNET)</bold>
              </th>
              <th rowspan="1" colspan="1">
                <bold><italic toggle="yes">P</italic>-value</bold>
              </th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Positive regulation of transcription, DNA-templated (GO:0045893)</td>
              <td rowspan="1" colspan="1">6.05E-41</td>
              <td rowspan="1" colspan="1">Carcinogenesis</td>
              <td rowspan="1" colspan="1">1.39E-55</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Regulation of transcription by RNA polymerase II (GO:0006357)</td>
              <td rowspan="1" colspan="1">2.28E-29</td>
              <td rowspan="1" colspan="1">Malignant neoplasm of breast</td>
              <td rowspan="1" colspan="1">1.64E-54</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Positive regulation of transcription by RNA polymerase II (GO:0045944)</td>
              <td rowspan="1" colspan="1">4.79E-29</td>
              <td rowspan="1" colspan="1">Breast Carcinoma</td>
              <td rowspan="1" colspan="1">2.31E-53</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Negative regulation of transcription, DNA-templated (GO:0045892)</td>
              <td rowspan="1" colspan="1">6.06E-29</td>
              <td rowspan="1" colspan="1">Malignant neoplasm of prostate</td>
              <td rowspan="1" colspan="1">3.05E-52</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Regulation of transcription, DNA-templated (GO:0006355)</td>
              <td rowspan="1" colspan="1">1.60E-27</td>
              <td rowspan="1" colspan="1">Neoplasm Metastasis</td>
              <td rowspan="1" colspan="1">3.88E-52</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>The overlap of our inferred drivers and the top three GO Biological Terms (2021)
resulting from enrichment analysis are as follows: for drivers inferred by using
‘VIMtime(SC)’, positive regulation of transcription, DNA-templated (GO:0045893) (125/545,
<italic toggle="yes">P</italic>-value 6.05E-41), regulation of transcription by RNA polymerase II
(GO:0006357) (154/545, <italic toggle="yes">P</italic>-value 2.28E-29) and positive regulation of
transcription by RNA polymerase II (GO:0045944) (93/545, 4.79E-29). For drivers discovered
by following ‘HER2time(SC)’, positive regulation of transcription, DNA-templated
(GO:0045893) (144/604, <italic toggle="yes">P</italic>-value 2.06E-49), positive regulation of
transcription by RNA polymerase II (GO:0045944) (114/604, <italic toggle="yes">P</italic>-value
6.47E-40) and regulation of transcription by RNA polymerase II (GO:0006357) (173/604,
<italic toggle="yes">P</italic>-value 1.01E-33).</p>
      <p>Similarly, overlap between our inferred set of drivers and DisGeNET cancer associated
genes includes a significant number of genes. Overlaps of our inferred drivers and the top
three GDAs terms resulting from DisGeNET analysis are as follows: for drivers inferred by
using ‘VIMtime(SC)’, cancinogenes (273/545, <italic toggle="yes">P</italic>-value 1.39E-55), malignant
neoplasm of breast (306/545, <italic toggle="yes">P</italic>-value 1.64E-54) and breast carcinoma
(301/545, <italic toggle="yes">P</italic>-value 2.31E-53). For drivers discovered by following
‘HER2time(SC)’, mammary neoplasm (244/604, <italic toggle="yes">P</italic>-value 1.71E-73), malignant
neoplasm of breast (353/604, <italic toggle="yes">P</italic>-value 4.62E-69) and breast carcinoma
(348/604, <italic toggle="yes">P</italic>-value 4.75E-68). These results suggest our inferred driver
genes are significantly related to cancer.</p>
    </sec>
    <sec id="sec3e">
      <title>3.4 Dynamic information enhance drivers discovery from bulk data</title>
      <p>Cancer data from cross-sectional data, also known as bulk data, account for the current
majority of data from cancer patients. For such a reason, significant coordinated efforts
have been made to create repositories hosting bulk data useful for research purposes. As
an example, <italic toggle="yes">the cancer genome atlas (TCGA)</italic> program (<ext-link xlink:href="https://www.cancer.gov/tcga" ext-link-type="uri">https://www.cancer.gov/tcga</ext-link>)
provides a comprehensive collection of genomic, epigenomic, transcriptomic and proteomic
cancer data [<xref rid="ref23" ref-type="bibr">23</xref>]. Availability of these datasets
is one of the reasons most of the current methods for driver discovery are designed for
bulk data.</p>
      <p>To further assess the performance of our method, and validate whether including dynamic
causal inference procedures enhance the ability to identify driver genes from bulk data,
we applied our method to the TCGA–BRCA cancer dataset. Data used for this analysis were
downloaded using the <italic toggle="yes">TCGAbiolinks</italic> package [<xref rid="ref45" ref-type="bibr">45</xref>]. A total of 752 primary solid tumours samples from 747
patients were selected, corresponding to the same patients analysed by Pham et al. [<xref rid="ref8" ref-type="bibr">8</xref>]. Data downloaded consist of gene expression (raw
counts) harmonized against GRCh38 (hg38). The dataset after removing low expressed genes
has 19 351 genes. To allow a fair comparison with mutation-based approaches, we ranked our
discoveries by frequency of single nucleotide variations in this dataset (the more times
the gene appears as mutated, the higher the rank). Mutational information was obtained
from Mutation Annotation Format (MAF) (MAF.hg38) by using
<italic toggle="yes">TCGAbiolinks</italic>.</p>
      <p>We normalized this dataset in order to compensate within samples and cross-sectional
samples effects. This normalization was performed by using the
<italic toggle="yes">TCGAanalyze_Normalization</italic> method from <italic toggle="yes">TCGAbiolinks</italic>
package, which uses procedures to adjust for GC-content effect on read counts [<xref rid="ref46" ref-type="bibr">46</xref>]. VIM and HER2 gene expression after normalization
are used as path covariates to find the corresponding ‘VIMtime(Bulk)’ and ‘HER2time(Bulk)’
<italic toggle="yes">pseudotime</italic> orders from this dataset. We used the COSMIC CGC (v94,
n=719) as the reference set of CCG genes.</p>
      <p>Performance of a method is assessed based on the total of CGC genes such a method is able
to identify. The more CGC genes the method recall, the better the method is. To facilitate
the comparison, we explore the performance of the benchmarked methods in the top 50, 100,
150 and 200 drivers predicted by each of them. OncodriveCLUST, OncodriveFM and NetSig
utilize corrected <italic toggle="yes">P</italic>-value to rank their discoveries. ActiveDriver and
DriverNet inferred genes are ranked by <italic toggle="yes">P</italic>-value. DawnRank provides its own
ranking scores. CBNA also provides its own ranking based on the mutation frequency of
genes. Results of performance are summarized in Figure <xref rid="f5" ref-type="fig">5</xref>.</p>
      <fig position="float" id="f5">
        <label>Figure 5</label>
        <caption>
          <p>Comparison of different cancer drivers inference methods for bulk data. We
benchmarked the performance of our method against seven other methods for cancer
driver discovery. We use CGC genes as a conservative approximation of the ground truth
as the full set of cancer driver genes remains still unknown. We present the results
for top N =50,100,150,200 genes following each method’s rank. For a fair comparison
with other mutational approaches, we ranked our inferred genes following mutation
frequency in TCGA–BRCA dataset.</p>
        </caption>
        <graphic xlink:href="elac030f5" position="float"/>
      </fig>
      <p>The last three bars of each of the analysed top 50, 100, 150 and 200 drivers shown in
Figure <xref rid="f5" ref-type="fig">5</xref> correspond to the performance of our method
for drivers inferred from ‘HER2time(Bulk)’, ‘VIMtime(Bulk)’ and combined (union set),
respectively. In general, our method outperforms other methods when inference was made
following <italic toggle="yes">EMT</italic> process (VIMtime) and combined (union of the two inferred
sets). Inference performance following ‘HER2time’ of our method is comparable with CBNA,
and outperforms other methods. These results suggest our method is able to identify
mutated cancer drivers even when mutational information is not used during the inference
process. Furthermore, these results also suggest that including information of the
underlying dynamics (as well as causality) can enhance the ability for cancer drivers
discovery, even in bulk data. The top 100 <italic toggle="yes"><bold>dynamic cancer
drivers</bold></italic> inferred from ‘HER2time(Bulk)’, and the top 100 from
‘VIMtime(Bulk)’ are shown in <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">supplementary material</xref></italic> (<italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Supplementary table 8</xref></italic> and
<italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Supplementary table
9</xref></italic>). The full list of <italic toggle="yes"><bold>dynamic cancer
drivers</bold></italic> discovered in our experiments form bulk data can be found in the
<italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Supplementary</xref></italic> folder at <ext-link xlink:href="https://github.com/AndresMCB/DynamicCancerDriver" ext-link-type="uri">https://github.com/AndresMCB/DynamicCancerDriver</ext-link>.</p>
    </sec>
    <sec id="sec3f">
      <title>3.5 Gene regulatory networks for dynamic cancer driver genes</title>
      <p>We explored possible regulatory relationships among our dynamic cancer drivers and the
GCG genes that are marked as breast cancer drivers by the COSMIC project. We retrieve
regulatory relationships from the top 200 inferred DCD by using HER2 as path covariate
(for both single-cell and bulk data), and the genes detected by our method that are marked
as breast cancer driver in COSMIC Cancer Gene Census database [<xref rid="ref24" ref-type="bibr">24</xref>]. Regulatory relationships are extracted from the website
<ext-link xlink:href="http://www.grndb.com" ext-link-type="uri">http://www.grndb.com</ext-link> [<xref rid="ref47" ref-type="bibr">47</xref>]. We have only used the regulatory relationships from Breast
Invasive Carcinoma (BRCA–TCGA) data and kept only the relationships with high confidence.
The result contains 93 699 regulatory relationships. From this result we extract all
relationships between the top 200 of DCDs and the set (not restricted to the top 200 DCDs)
of CGC Breast Cancer drivers detected by our method (when using ‘HER2time(SC)’ and
‘HER2time(Bulk)’, respectively).</p>
      <p>Following this procedure, a total of 81 regulatory relationships were detected among the
DCD genes discovered from single-cell data. Similarly, a total of 56 regulatory
relationships between DCD genes were detected from bulk data. In both cases, broadly
accepted breast cancer drivers such as BRCA1 and ESR1 are central nodes in the network
(Figure <xref rid="f6" ref-type="fig">6</xref>).The network analysis has revealed several
influential DCDs that are not curated CGC genes yet, for example E2F2 and THRA from
single-cell (Figure <xref rid="f6" ref-type="fig">6</xref> A), and SIN3A from bulk data
(Figure <xref rid="f6" ref-type="fig">6</xref> B). E2F2 has been linked to tumourigenesis,
metastasis and poor overall survival in breast cancer [<xref rid="ref48" ref-type="bibr">48</xref>]. THRA has been found to be correlated with high breast cancer mortality
[<xref rid="ref49" ref-type="bibr">49</xref>], and SIN3A mutations in breast cancer
enhances cell proliferation [<xref rid="ref50" ref-type="bibr">50</xref>]. The list of
regulatory relationships used for plotting Figure 6 can be found in <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Supplementary table 10</xref></italic>
(‘DCD(HER2_SC) Reg. relationships’), and <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Supplementary table 11</xref></italic> (‘DCD(HER2_Bulk) Reg.
relationships’).</p>
      <fig position="float" id="f6">
        <label>Figure 6</label>
        <caption>
          <p>Regulatory relationships among DCDs. Gene Regulatory Networks showing genes in the
union set of top 200 DCDs (blue) and the total of CGG breast cancer drivers identified
as DCD (magenta). Network analysis reveals novel drivers that are highly influential
in the network such as E2F2 and THRA from single cell (Figure <xref rid="f6" ref-type="fig">6</xref> A), and SIN3A from bulk data (Figure <xref rid="f6" ref-type="fig">6</xref> B).</p>
        </caption>
        <graphic xlink:href="elac030f6" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec4">
    <title>4 Discussion and Conclusions</title>
    <p>In this paper, we have presented a new dynamic causal inference method for cancer driver
discovery. Our approach considers cancer drivers as genes driving one or more biological
processes leading to cancer. Based on this consideration, our method hypothesize that driver
genes are driving the dynamics of biological processes pathologically altered and its causal
influence in cancer development is reflected on its own gene expression.</p>
    <p>To verify this hypothesis, our method performs a data transformation to unveil the
underlying dynamics linked to one (or more) trajectories of interest and verifies the
possible causal link between putative drivers and the progression of the biological
trajectory. Furthermore, we identify the sample that represents the most significant change
along the biological transition. We use that sample to determine the <italic toggle="yes">Causal
Impact</italic> of the driver. If such an impact is significant, the gene is considered a
cancer driver for our method.</p>
    <p>In our method we use a PPI network to guide a knowledge-based feature selection to define
our putative drivers. However, hub genes obtained from hub identification methods and other
methods for finding important genes from Gene Regulatory Networks (please check [<xref rid="ref51" ref-type="bibr">51</xref>] for a comprehensive review of GRN methods for
single cell) are also suitable putative drivers for our DCD framework. Our causal inference
method carefully explores such influential genes to identify <bold><italic toggle="yes">dynamic cancer
drivers</italic></bold> by assessing the causal effects of the putative drivers on
cancer reflected in the pseudotime ordered gene expression of those putative drivers.</p>
    <p>In this paper, we used HER2 and VIM to demonstrate our causal framework. However, our DCD
method allows the use of other known breast cancer drivers as well, for example ESR1
(details of experiment results in <xref rid="sup1" ref-type="supplementary-material">supplementary material</xref>, Section 3.). This capability can be extrapolated to the
known drivers of other cancer types. As a result, the DCD approach is also suitable for
detecting drivers in other cancer types/subtypes when some driver genes are known.</p>
    <p>One interesting point of our method is that it can detect drivers that are not
differentially expressed. Our experiment results (see <xref rid="sup1" ref-type="supplementary-material">supplementary material—Section 4</xref> for
details) show that 65 inferred DCDs (in the top 100 when using HER2time(Bulk)) are not DEGs
between the conditions normal/cancer, including eight CGC Breast Cancer Drivers (i.e.
PIK3CA, CDH1, NCOR1, MAP2K4, AKT1, CASP8, EP300 and CTCF). These results suggest that some
cancer drivers’ gene expression changes are subtle enough to prevent them from being
detected by DEGs analysis, and yet significantly alter the dynamics of some biological
processes, causing cancer development.</p>
    <p>Additional experiments comparing <italic toggle="yes">PhenoPath</italic> (native), and an externally
provided pseudotime (i.e. <italic toggle="yes">Monocle3</italic>, a popular method for pseudotime
inference [<xref rid="ref52" ref-type="bibr">52</xref>, <xref rid="ref53" ref-type="bibr">53</xref>]), have shown that our method can detect DCD genes from externally provided
pseudotimes (details of the experiments can be found in <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">supplementary material—Section
5</xref></italic>). <italic toggle="yes">PhenoPath</italic> allows to orient the inferred trajectory to
fit a biological process of interest by using a covariate related to such a trajectory. Due
to this capability of <italic toggle="yes">PhenoPath</italic> we can infer drivers of different
biological processes leading to cancer progression, while other pseudotime inference methods
lack this capability. As a result, in our experiments the DCD method could identify more
novel drivers from different path covariates when using <italic toggle="yes">PhenoPath</italic>,
supporting our hypothesis that different biological processes have different set of driver
genes.</p>
    <p>Experiments with the data used imply the superior performance of our method. We have
assessed our method’s ability to detect novel drivers that can be used for expanding current
cancer drivers catalogues, identifying simultaneously experimentally confirmed drivers. Our
analyses suggest that <italic toggle="yes"><bold>dynamic cancer driver</bold></italic> concept is useful
to expand the spectrum of current cancer drivers catalogues. Additionally, our method
performs well in both single-cell and bulk data, outperforming all other analysed methods in
terms of the number confirmed drivers that were predicted for each method when using bulk
data. The results of our tests suggest that making use of the temporal information of
biological processes significantly improves cancer driver discovery. Additionally, our
experiments suggest that some cancer drivers significantly influence more than one
biological trajectory along cancer progression.</p>
    <boxed-text id="box01" position="float">
      <sec id="sec19u">
        <title>Key points</title>
        <list list-type="bullet">
          <list-item>
            <p>We hypothesize that there are multiple biological processes driving cancer and each
of the processes has its own drivers.</p>
          </list-item>
          <list-item>
            <p>Our method incorporates aspects from the underlying dynamics of cancer development
to a causal inference approach, allowing us to uncover causal relationship of genes
driving core biological process in cancer development.</p>
          </list-item>
          <list-item>
            <p>Our experiments suggest that our approach is useful for expanding cancer drivers
catalogues by including novel cancer drivers that are not detected by methods based
on static data.</p>
          </list-item>
          <list-item>
            <p>Due to the dynamic nature of our causal approach, our method complements current
well-recognized cancer drivers discovery methods based on static data.</p>
          </list-item>
        </list>
      </sec>
    </boxed-text>
  </sec>
  <sec id="sec5">
    <title>5 Author contributions statement</title>
    <p>A.C. and T.L. conceived the experiments, A.C., V.P. and X.L. conducted the experiments.
A.C. and T.L analysed the results. A.C. and T.L. wrote the manuscript. V.P., X.L, L.L. and
J.L. reviewed the manuscript.</p>
  </sec>
  <sec id="sec6">
    <title>6 Data and code availability</title>
    <p>Single-cell data used in our experiments are publicly available at NCBI GEO database, under
accession number GSE75688 at (<ext-link xlink:href="https://www.ncbi.nlm.nih.gov/geo/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/geo/</ext-link>). TCGA-BRCA dataset can be accessed at
<ext-link xlink:href="https://portal.gdc.cancer.gov/" ext-link-type="uri">https://portal.gdc.cancer.gov/</ext-link>. An
R data version of all datasets, and codes used in this paper (including the R-package with
the implementation of our method) can be found at <ext-link xlink:href="https://github.com/AndresMCB/DynamicCancerDriver" ext-link-type="uri">https://github.com/AndresMCB/DynamicCancerDriver</ext-link>.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>Supplementary_material_elac030</label>
      <media xlink:href="supplementary_material_elac030.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ack1">
    <title>Acknowledgments</title>
    <p>The authors thank the anonymous reviewers for their valuable suggestions. This work is
supported in part by funds from the Australian Technology Network ATN-LATAM Research
Scholarship Scheme, and Australian Research Council ARC - Discovery Early Career Researcher
Award (DECRA, DE 200100200).</p>
  </ack>
  <notes id="bio3">
    <title>Author Biographies</title>
    <p><bold>Andres M. Cifuentes-Bernal</bold> received his B.Sc. degree in Mechatronics from the
National University of Colombia and his M.Sc. degree in Mechatronics from the Nueva
Granada Military University, Colombia, in 2009 and 2015, respectively. He was a professor
in the Nueva Granada Military University and he is co-inventor of three Colombian Patents.
He is currently working towards the PhD degree in Mathematics and Computer Science
(Bioinformatics) at University of South Australia. His research interest include
bioinformatics, dynamic causal discovery and control system design.</p>
    <sec sec-type="author-bio" id="sec12a">
      <p><bold>Vu VH Pham</bold> received his Master degree in Information Technology from the
Deakin University, Australia in 2017, and his Ph.D. degree from the School of Information
Technology and Mathematical Sciences, University of South Australia (UniSA) in 2021. His
research interests include causal inference methods and their applications in
Bioinformatics.</p>
    </sec>
    <sec sec-type="author-bio" id="sec12b">
      <p><bold>Xiaomei Li</bold> received the M.S. degree in computer science from Fuzhou
University, China, in 2011. She is currently pursuing the Ph.D. degree with the University
of South Australia. Her research focuses on the development of computational methods for
cancer subtype and prognosis based on bulk data and single-cell sequencing data.</p>
    </sec>
    <sec sec-type="author-bio" id="sec12c">
      <p><bold>Lin Liu</bold> received the bachelor’s and master’s degrees in electronic
engineering from Xidian University, China, in 1991 and 1994, respectively, and the PhD
degree in computer systems engineering from the University of South Australia, in 2006.
She is currently an associated professor with the University of South Australia. Her
research interests include data mining, causal inference and bioinformatics</p>
    </sec>
    <sec sec-type="author-bio" id="sec12d">
      <p><bold>Jiuyong Li</bold> (Member, IEEE) received the Ph.D. degree in computer science from
Griffith University, Brisbane, Australia, in 2002. He is currently a Professor with the
University of South Australia (UniSA), Mawson Lakes, SA, Australia. His research work has
been supported by seven Australian Research Council Discovery projects. He has led several
industrial and applied projects. His main research interests include data mining, causal
discovery, privacy and fairness and bioinformatics. Li is also a member of the Australian
Computer Society National Committee for Artificial Intelligence.</p>
    </sec>
    <sec sec-type="author-bio" id="sec12e">
      <p><bold>Thuc Duy Le</bold> is currently an associate Professor with the UniSA STEM unit,
University of South Australia. His research interest includes causal discovery methods and
their applications in bioinformatics. He is also a DECRA Fellow, for the period of
2020–2022. He has served as an Academic Editor for PLOS One, and and BMC Cancer and a
reviewer for many top conferences and journals in data mining and bioinformatics.</p>
    </sec>
  </notes>
  <ref-list id="bib1">
    <title>References</title>
    <ref id="ref1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nik-Zainal</surname>  <given-names>S</given-names></string-name>,
<string-name><surname>Davies</surname>  <given-names>H</given-names></string-name>,
<string-name><surname>Staaf</surname>  <given-names>J</given-names></string-name>,
<etal>et al.</etal></person-group>  <article-title>Landscape of somatic mutations in
560 breast cancer whole-genome sequences</article-title>. <source>Nature</source>
 <year>2016</year>;<volume>534</volume>(<issue>7605</issue>):<fpage>47</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">27135926</pub-id></mixed-citation>
    </ref>
    <ref id="ref2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dietlein</surname>  <given-names>F</given-names></string-name>,
<string-name><surname>Weghorn</surname>  <given-names>D</given-names></string-name>,
<string-name><surname>Taylor-Weiner</surname>
 <given-names>A</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>Identification of cancer driver genes based on nucleotide
context</article-title>. <source>Nat Genet</source>
 <year>2020</year>;<volume>52</volume>(<issue>2</issue>):<fpage>208</fpage>–<lpage>18</lpage>.<pub-id pub-id-type="pmid">32015527</pub-id></mixed-citation>
    </ref>
    <ref id="ref3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Neyshabouri</surname>  <given-names>MM</given-names></string-name>,
<string-name><surname>Jun</surname>  <given-names>S-H</given-names></string-name>,
<string-name><surname>Lagergren</surname>
 <given-names>J</given-names></string-name></person-group>. <article-title>Inferring
tumor progression in large datasets</article-title>. <source>PLoS Comput Biol</source>
 <year>2020</year>;<volume>16</volume>(<issue>10</issue>):<fpage>1</fpage>–<lpage>16</lpage>.</mixed-citation>
    </ref>
    <ref id="ref4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bailey</surname>  <given-names>MH</given-names></string-name>,
<string-name><surname>Tokheim</surname>  <given-names>C</given-names></string-name>,
<string-name><surname>Porta-Pardo</surname>
 <given-names>E</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>Comprehensive characterization of cancer driver genes and
mutations</article-title>. <source>Cell</source>
 <year>2018</year>;<volume>173</volume>(<issue>2</issue>):<fpage>371</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="pmid">29625053</pub-id></mixed-citation>
    </ref>
    <ref id="ref5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bracken</surname>  <given-names>CP</given-names></string-name>,
<string-name><surname>Scott</surname>  <given-names>HS</given-names></string-name>,
<string-name><surname>Goodall</surname>
 <given-names>GJ</given-names></string-name></person-group>. <article-title>A
network-biology perspective of microrna function and dysfunction in
cancer</article-title>. <source>Nat Rev Genet</source>
 <year>2016</year>;<volume>17</volume>:<fpage>719</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">27795564</pub-id></mixed-citation>
    </ref>
    <ref id="ref6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname>  <given-names>H-M</given-names></string-name>,
<string-name><surname>Kuang</surname>  <given-names>S</given-names></string-name>,
<string-name><surname>Xiong</surname>  <given-names>X</given-names></string-name>,
<etal>et al.</etal></person-group>  <article-title>Transcription factor and microrna
co-regulatory loops: important regulatory motifs in biological processes and
diseases</article-title>. <source>Brief Bioinform</source>
 <year>2015</year>;<volume>16</volume>:<fpage>45</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="pmid">24307685</pub-id></mixed-citation>
    </ref>
    <ref id="ref7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barabási</surname>  <given-names>A-L</given-names></string-name>,
<string-name><surname>Gulbahce</surname>
 <given-names>N</given-names></string-name>, <string-name><surname>Loscalzo</surname>
 <given-names>J</given-names></string-name></person-group>. <article-title>Network
medicine: a network-based approach to human disease</article-title>. <source>Nat Rev
Genet</source>
 <year>2011</year>;<volume>12</volume>:<fpage>56</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="pmid">21164525</pub-id></mixed-citation>
    </ref>
    <ref id="ref8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pham</surname>  <given-names>VVH</given-names></string-name>,
<string-name><surname>Liu</surname>  <given-names>L</given-names></string-name>,
<string-name><surname>Bracken</surname>
 <given-names>CP</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>Cbna: A control theory based method for identifying coding and
non-coding cancer drivers</article-title>. <source>PLoS Comput Biol</source>
 <year>2019</year>;<volume>15</volume>(<issue>12</issue>):<elocation-id>e1007538</elocation-id>.<pub-id pub-id-type="pmid">31790386</pub-id></mixed-citation>
    </ref>
    <ref id="ref9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Horn</surname>  <given-names>H</given-names></string-name>,
<string-name><surname>Lawrence</surname>
 <given-names>MS</given-names></string-name>,
<string-name><surname>Chouinard</surname>
 <given-names>CR</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>Netsig: network-based discovery from cancer genomes</article-title>.
<source>Nat Methods</source>
 <year>2018</year>;<volume>15</volume>(<issue>1</issue>):<fpage>61</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">29200198</pub-id></mixed-citation>
    </ref>
    <ref id="ref10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pham</surname>  <given-names>VVH</given-names></string-name>,
<string-name><surname>Lin</surname>  <given-names>L</given-names></string-name>,
<string-name><surname>Bracken</surname>  <given-names>C</given-names></string-name>,
<etal>et al.</etal></person-group>  <article-title>Computational methods for cancer
driver discovery: A survey</article-title>. <source>Theranostics</source>
 <year>2021</year>;<volume>11</volume>:<fpage>5553</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="pmid">33859763</pub-id></mixed-citation>
    </ref>
    <ref id="ref11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fan</surname>  <given-names>J</given-names></string-name>,
<string-name><surname>Slowikowski</surname>
 <given-names>K</given-names></string-name>, <string-name><surname>Zhang</surname>
 <given-names>F</given-names></string-name></person-group>.
<article-title>Single-cell transcriptomics in cancer: computational challenges and
opportunities</article-title>. <source>Exp Mol Med</source>
 <year>2020</year>;<volume>52</volume>(<issue>9</issue>):<fpage>1452</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="pmid">32929226</pub-id></mixed-citation>
    </ref>
    <ref id="ref12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lu</surname>  <given-names>L</given-names></string-name>,
<string-name><surname>McCurdy</surname>  <given-names>S</given-names></string-name>,
<string-name><surname>Huang</surname>  <given-names>S</given-names></string-name>,
<etal>et al.</etal></person-group>  <article-title>Time series mirna-mrna integrated
analysis reveals critical mirnas and targets in macrophage polarization</article-title>.
<source>Sci Rep</source>
 <year>2016</year>;<volume>6</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">28442746</pub-id></mixed-citation>
    </ref>
    <ref id="ref13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>  <given-names>N</given-names></string-name>,
<string-name><surname>Zheng</surname>  <given-names>J</given-names></string-name>,
<string-name><surname>Chen</surname>  <given-names>Z</given-names></string-name>,
<etal>et al.</etal></person-group>  <article-title>Single-cell microrna-mrna
co-sequencing reveals non-genetic heterogeneity and mechanisms of microrna
regulation</article-title>. <source>Nat Commun</source>
 <year>2019</year>;<volume>10</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">30602773</pub-id></mixed-citation>
    </ref>
    <ref id="ref14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reid</surname>  <given-names>JE</given-names></string-name>,
<string-name><surname>Wernisch</surname>
 <given-names>L</given-names></string-name></person-group>. <article-title>Pseudotime
estimation: deconfounding single cell time series</article-title>.
<source>Bioinformatics</source>
 <year>2016</year>;<volume>32</volume>(<issue>19</issue>):<fpage>2973</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="pmid">27318198</pub-id></mixed-citation>
    </ref>
    <ref id="ref15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Campbell</surname>  <given-names>KR</given-names></string-name>,
<string-name><surname>Yau</surname>
 <given-names>C</given-names></string-name></person-group>. <article-title>Uncovering
pseudotemporal trajectories with covariates from single cell and bulk expression
data</article-title>. <source>Nat Commun</source>
 <year>2018</year>;<volume>9</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">29317637</pub-id></mixed-citation>
    </ref>
    <ref id="ref16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sun</surname>  <given-names>X</given-names></string-name>,
<string-name><surname>Zhang</surname>  <given-names>J</given-names></string-name>,
<string-name><surname>Nie</surname>
 <given-names>Q</given-names></string-name></person-group>. <article-title>Inferring
latent temporal progression and regulatory networks from cross-sectional transcriptomic
data of cancer samples</article-title>. <source>PLoS Comput Biol</source>
 <year>2021</year>;<volume>17</volume>(<issue>3</issue>):<elocation-id>e1008379</elocation-id>.<pub-id pub-id-type="pmid">33667222</pub-id></mixed-citation>
    </ref>
    <ref id="ref17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cifuentes-Bernal</surname>  <given-names>AM</given-names></string-name>,
<string-name><surname>Pham</surname>  <given-names>VV</given-names></string-name>,
<string-name><surname>Li</surname>  <given-names>X</given-names></string-name>,
<etal>et al.</etal></person-group>  <article-title>A pseudotemporal causality approach
to identifying mirna–mrna interactions during biological processes</article-title>.
<source>Bioinformatics</source>
 <year>2021</year>;<volume>37</volume>(<issue>6</issue>):<fpage>807</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">33070184</pub-id></mixed-citation>
    </ref>
    <ref id="ref18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jin</surname>  <given-names>T</given-names></string-name>,
<string-name><surname>Nguyen</surname>  <given-names>ND</given-names></string-name>,
<string-name><surname>Talos</surname>  <given-names>F</given-names></string-name>,
<string-name><surname>Wang</surname>
 <given-names>D</given-names></string-name></person-group>. <article-title>Ecmarker:
Interpretable machine learning model identifies gene expression biomarkers predicting
clinical outcomes and reveals molecular mechanisms of human disease in early
stages</article-title>. <source>Bioinformatics</source>
 <year>2021</year>;<volume>37</volume>(<issue>8</issue>):<fpage>1115</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">33305308</pub-id></mixed-citation>
    </ref>
    <ref id="ref19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nishiyama</surname>  <given-names>Y</given-names></string-name>,
<string-name><surname>Saikawa</surname>  <given-names>Y</given-names></string-name>,
<string-name><surname>Nishiyama</surname>
 <given-names>N</given-names></string-name></person-group>. <article-title>Interaction
between the immune system and acute myeloid leukemia: A model incorporating promotion of
regulatory t cell expansion by leukemic cells</article-title>.
<source>Biosystems</source>
 <year>2018</year>;<volume>165</volume>:<fpage>99</fpage>–<lpage>105</lpage>.<pub-id pub-id-type="pmid">29408212</pub-id></mixed-citation>
    </ref>
    <ref id="ref20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>  <given-names>H</given-names></string-name>,
<string-name><surname>Wei</surname>  <given-names>Q</given-names></string-name>,
<string-name><surname>Zhong</surname>  <given-names>X</given-names></string-name>,
<etal>et al.</etal></person-group>  <article-title>Cancer driver gene discovery
through an integrative genomics approach in a non-parametric bayesian
framework</article-title>. <source>Bioinformatics</source>
 <year>2017</year>;<volume>33</volume>(<issue>4</issue>):<fpage>483</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">27797769</pub-id></mixed-citation>
    </ref>
    <ref id="ref21">
      <label>21.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Campbell</surname>  <given-names>K</given-names></string-name></person-group>. <source>phenopath: Genomic trajectories with heterogeneous genetic and
environmental backgrounds</source>, <year>2021</year>, <comment>R package version
1.16.0</comment>.</mixed-citation>
    </ref>
    <ref id="ref22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chung</surname>  <given-names>W</given-names></string-name>,
<string-name><surname>Eum</surname>  <given-names>HH</given-names></string-name>,
<string-name><surname>Lee</surname>  <given-names>H-O</given-names></string-name>,
<etal>et al.</etal></person-group>  <article-title>Single-cell rna-seq enables
comprehensive tumour and immune cell profiling in primary breast cancer</article-title>.
<source>Nat Commun</source>
 <year>2017</year>;<volume>8</volume>(<issue>1</issue>):<elocation-id>15081</elocation-id>.<pub-id pub-id-type="pmid">28474673</pub-id></mixed-citation>
    </ref>
    <ref id="ref23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weinstein</surname>  <given-names>JN</given-names></string-name>,
<string-name><surname>Collisson</surname>
 <given-names>EA</given-names></string-name>, <string-name><surname>Mills</surname>
 <given-names>GB</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>The cancer genome atlas pan-cancer analysis project</article-title>.
<source>Nat Genet</source>
 <year>2013</year>;<volume>45</volume>(<issue>10</issue>):<fpage>1113</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">24071849</pub-id></mixed-citation>
    </ref>
    <ref id="ref24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sondka</surname>  <given-names>Z</given-names></string-name>,
<string-name><surname>Bamford</surname>  <given-names>S</given-names></string-name>,
<string-name><surname>Cole</surname>  <given-names>CG</given-names></string-name>,
<etal>et al.</etal></person-group>  <article-title>The cosmic cancer gene census:
describing genetic dysfunction across all human cancers</article-title>. <source>Nat Rev
Cancer</source>
 <year>2018</year>;<volume>18</volume>(<issue>11</issue>):<fpage>696</fpage>–<lpage>705</lpage>.<pub-id pub-id-type="pmid">30293088</pub-id></mixed-citation>
    </ref>
    <ref id="ref25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brodersen</surname>  <given-names>KH</given-names></string-name>,
<string-name><surname>Gallusser</surname>
 <given-names>F</given-names></string-name>, <string-name><surname>Koehler</surname>
 <given-names>J</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>Inferring causal impact using bayesian structural time-series
models</article-title>. <source>Annals of Applied Statistics</source>
 <year>2015</year>;<volume>9</volume>:<fpage>247</fpage>–<lpage>74</lpage>.</mixed-citation>
    </ref>
    <ref id="ref26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vinayagam</surname>  <given-names>A</given-names></string-name>,
<string-name><surname>Stelzl</surname>  <given-names>U</given-names></string-name>,
<string-name><surname>Foulle</surname>  <given-names>R</given-names></string-name>,
<etal>et al.</etal></person-group>  <article-title>A directed protein interaction
network for investigating intracellular signal transduction</article-title>. <source>Sci
Signal</source>
 <year>2011</year>;<volume>4</volume>(<issue>189</issue>):<fpage>rs8</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">21900206</pub-id></mixed-citation>
    </ref>
    <ref id="ref27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abadie</surname>  <given-names>A</given-names></string-name>,
<string-name><surname>Diamond</surname>  <given-names>A</given-names></string-name>,
<string-name><surname>Hainmueller</surname>
 <given-names>J</given-names></string-name></person-group>. <article-title>Synthetic
control methods for comparative case studies: Estimating the effect of california’s
tobacco control program</article-title>. <source>J Am Stat Assoc</source>
 <year>2010</year>;<volume>105</volume>(<issue>490</issue>):<fpage>493</fpage>–<lpage>505</lpage>.</mixed-citation>
    </ref>
    <ref id="ref28">
      <label>28.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Koller</surname>  <given-names>D</given-names></string-name>,
<string-name><surname>Friedman</surname>
 <given-names>N</given-names></string-name></person-group>. <source>Probabilistic
graphical models: principles and techniques</source>. <publisher-name>MIT
press</publisher-name>, <year>2009</year>.</mixed-citation>
    </ref>
    <ref id="ref29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scott</surname>  <given-names>SL</given-names></string-name>,
<string-name><surname>Varian</surname>
 <given-names>H</given-names></string-name></person-group>. <article-title>Predicting
the present with bayesian structural time series</article-title>. <source>International
Journal of Mathematical Modelling and Numerical Optimisation</source>
 <year>2014</year>;<volume>5</volume>:<fpage>4</fpage>–<lpage>23</lpage>.</mixed-citation>
    </ref>
    <ref id="ref30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jinwen Qiu</surname>  <given-names>S</given-names></string-name>,
<string-name><surname>Jammalamadaka</surname>
 <given-names>R</given-names></string-name>, <string-name><surname>Ning</surname>
 <given-names>N</given-names></string-name></person-group>.
<article-title>Multivariate bayesian structural time series model</article-title>.
<source>J Mach Learn Res</source>
 <year>2018</year>;<volume>19</volume>(<issue>1</issue>):<fpage>2744</fpage>–<lpage>76</lpage>.</mixed-citation>
    </ref>
    <ref id="ref31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khan</surname>  <given-names>A</given-names></string-name>,
<string-name><surname>Mathelier</surname>
 <given-names>A</given-names></string-name></person-group>. <article-title>Intervene:
a tool for intersection and visualization of multiple gene or genomic region
sets</article-title>. <source>BMC bioinformatics</source>
 <year>2017</year>;<volume>18</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">28049414</pub-id></mixed-citation>
    </ref>
    <ref id="ref32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lawrence</surname>  <given-names>MS</given-names></string-name>,
<string-name><surname>Stojanov</surname>
 <given-names>P</given-names></string-name>, <string-name><surname>Mermel</surname>
 <given-names>CH</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>Discovery and saturation analysis of cancer genes across 21 tumour
types</article-title>. <source>Nature</source>
 <year>2014</year>;<volume>505</volume>(<issue>7484</issue>):<fpage>495</fpage>–<lpage>501</lpage>.<pub-id pub-id-type="pmid">24390350</pub-id></mixed-citation>
    </ref>
    <ref id="ref33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Martincorena</surname>  <given-names>I</given-names></string-name>,
<string-name><surname>Raine</surname>  <given-names>KM</given-names></string-name>,
<string-name><surname>Gerstung</surname>
 <given-names>M</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>Universal patterns of selection in cancer and somatic
tissues</article-title>. <source>Cell</source>
 <year>2017</year>;<volume>171</volume>(<issue>5</issue>):<fpage>1029</fpage>–<lpage>1041.e21</lpage>.<pub-id pub-id-type="pmid">29056346</pub-id></mixed-citation>
    </ref>
    <ref id="ref34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Priestley</surname>  <given-names>P</given-names></string-name>,
<string-name><surname>Baber</surname>  <given-names>J</given-names></string-name>,
<string-name><surname>Lolkema</surname>
 <given-names>MP</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>Pan-cancer whole-genome analyses of metastatic solid
tumours</article-title>. <source>Nature</source>
 <year>2019</year>;<volume>575</volume>(<issue>7781</issue>):<fpage>210</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">31645765</pub-id></mixed-citation>
    </ref>
    <ref id="ref35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rheinbay</surname>  <given-names>E</given-names></string-name>,
<string-name><surname>Nielsen</surname>
 <given-names>MM</given-names></string-name>, <string-name><surname>Abascal</surname>
 <given-names>F</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>Analyses of non-coding somatic drivers in 2,658 cancer whole
genomes</article-title>. <source>Nature</source>
 <year>2020</year>;<volume>578</volume>(<issue>7793</issue>):<fpage>102</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">32025015</pub-id></mixed-citation>
    </ref>
    <ref id="ref36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium</collab></person-group>. <article-title>Pan-cancer analysis of whole genomes</article-title>.
<source>Nature</source>
 <year>2020</year>;<volume>578</volume>(<issue>7793</issue>):<fpage>82</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">32025007</pub-id></mixed-citation>
    </ref>
    <ref id="ref37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abu-Thuraia</surname>  <given-names>A</given-names></string-name>,
<string-name><surname>Goyette</surname>
 <given-names>M-A</given-names></string-name>, <string-name><surname>Boulais</surname>
 <given-names>J</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>AXL confers cell migration and invasion by hijacking a PEAK1-regulated
focal adhesion protein network</article-title>. <source>Nat Commun</source>
 <year>2020</year>;<volume>11</volume>(<issue>1</issue>):<fpage>3586</fpage>.<pub-id pub-id-type="pmid">32681075</pub-id></mixed-citation>
    </ref>
    <ref id="ref38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aguilera</surname>  <given-names>TA</given-names></string-name>,
<string-name><surname>Rafat</surname>  <given-names>M</given-names></string-name>,
<string-name><surname>Castellini</surname>
 <given-names>L</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>Reprogramming the immunological microenvironment through radiation and
targeting axl</article-title>. <source>Nat Commun</source>
 <year>2016</year>;<volume>7</volume>(<issue>1</issue>):<elocation-id>13898</elocation-id>.<pub-id pub-id-type="pmid">28008921</pub-id></mixed-citation>
    </ref>
    <ref id="ref39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nagle</surname>  <given-names>AM</given-names></string-name>,
<string-name><surname>Levine</surname>  <given-names>KM</given-names></string-name>,
<string-name><surname>Tasdemir</surname>
 <given-names>N</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>Loss of e-cadherin enhances igf1–igf1r pathway activation and sensitizes
breast cancers to anti-igf1r/insr inhibitors</article-title>. <source>Clin Cancer
Res</source>
 <year>2018</year>;<volume>24</volume>(<issue>20</issue>):<fpage>5165</fpage>–<lpage>77</lpage>.<pub-id pub-id-type="pmid">29941485</pub-id></mixed-citation>
    </ref>
    <ref id="ref40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>  <given-names>B</given-names></string-name>,
<string-name><surname>Xiao Zeng</surname>
 <given-names>Y</given-names></string-name>, <string-name><surname>He</surname>
 <given-names>XW</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>Stc2 promotes the epithelial-mesenchymal transition of colorectal cancer
cells through akt-erk signaling pathways</article-title>. <source>Oncotarget</source>
 <year>2016</year>;<volume>7</volume>(<issue>44</issue>):<fpage>71400</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">27662663</pub-id></mixed-citation>
    </ref>
    <ref id="ref41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kilinc</surname>  <given-names>AN</given-names></string-name>,
<string-name><surname>Sugiyama</surname>
 <given-names>N</given-names></string-name>, <string-name><surname>Kalathur</surname>
 <given-names>RKR</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>Histone deacetylases, mbd3/nurd, and tet2 hydroxylase are crucial
regulators of epithelial-mesenchymal plasticity and tumor metastasis</article-title>.
<source>Oncogene</source>
 <year>2020</year>;<volume>39</volume>(<issue>7</issue>):<fpage>1498</fpage>–<lpage>513</lpage>.<pub-id pub-id-type="pmid">31666683</pub-id></mixed-citation>
    </ref>
    <ref id="ref42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stephen</surname>  <given-names>TL</given-names></string-name>,
<string-name><surname>Payne</surname>  <given-names>KK</given-names></string-name>,
<string-name><surname>Chaurio</surname>
 <given-names>RA</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>Satb1 expression governs epigenetic repression of pd-1 in tumor-reactive
t cells</article-title>. <source>Immunity</source>
 <year>2017</year>;<volume>46</volume>(<issue>1</issue>):<fpage>51</fpage>–<lpage>64</lpage>.<pub-id pub-id-type="pmid">28099864</pub-id></mixed-citation>
    </ref>
    <ref id="ref43">
      <label>43.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Liu</surname>  <given-names>C</given-names></string-name>,
<string-name><surname>Wang</surname>  <given-names>H</given-names></string-name>,
<string-name><surname>Wang</surname>  <given-names>W</given-names></string-name>,
<etal>et al.</etal></person-group>  <source>Eno2 promotes cell proliferation,
glycolysis, and glucocorticoid-resistance in acute lymphoblastic leukemia</source>,
<year>2018</year>.</mixed-citation>
    </ref>
    <ref id="ref44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Piñero</surname>  <given-names>J</given-names></string-name>,
<string-name><surname>Bravo</surname>  <given-names>A</given-names></string-name>,
<string-name><surname>Queralt-Rosinach</surname>
 <given-names>N</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>DisGeNET: a comprehensive platform integrating information on human
disease-associated genes and variants</article-title>. <source>Nucleic Acids
Res</source>
 <year>2016</year>;<volume>45</volume>(<issue>D1</issue>):<fpage>D833</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">27924018</pub-id></mixed-citation>
    </ref>
    <ref id="ref45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Colaprico</surname>  <given-names>A</given-names></string-name>,
<string-name><surname>Silva</surname>  <given-names>TC</given-names></string-name>,
<string-name><surname>Olsen</surname>  <given-names>C</given-names></string-name>,
<etal>et al.</etal></person-group>  <article-title>Tcgabiolinks: an r/bioconductor
package for integrative analysis of tcga data</article-title>. <source>Nucleic Acids
Res</source>
 <year>2016</year>;<volume>44</volume>(<issue>8</issue>):<fpage>e71</fpage>–<lpage>1</lpage>.<pub-id pub-id-type="pmid">26704973</pub-id></mixed-citation>
    </ref>
    <ref id="ref46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mounir</surname>  <given-names>M</given-names></string-name>,
<string-name><surname>Lucchetta</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Silva</surname>
 <given-names>TC</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>New functionalities in the tcgabiolinks package for the study and
integration of cancer data from gdc and gtex</article-title>. <source>PLoS Comput
Biol</source>
 <year>2019</year>;<volume>15</volume>(<issue>3</issue>):<elocation-id>e1006701</elocation-id>.<pub-id pub-id-type="pmid">30835723</pub-id></mixed-citation>
    </ref>
    <ref id="ref47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fang</surname>  <given-names>L</given-names></string-name>,
<string-name><surname>Yunjin Li</surname>
 <given-names>L</given-names></string-name>, <string-name><surname>Ma</surname>
 <given-names>QX</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>Grndb: decoding the gene regulatory networks in diverse human and mouse
conditions</article-title>. <source>Nucleic Acids Res</source>
 <year>2021</year>;<volume>49</volume>(<issue>D1</issue>):<fpage>D97</fpage>–<lpage>103</lpage>.<pub-id pub-id-type="pmid">33151298</pub-id></mixed-citation>
    </ref>
    <ref id="ref48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Andrechek</surname>  <given-names>ER</given-names></string-name></person-group>. <article-title>Her2/neu tumorigenesis and metastasis is regulated by e2f
activator transcription factors</article-title>. <source>Oncogene</source>
 <year>2015</year>;<volume>34</volume>(<issue>2</issue>):<fpage>217</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="pmid">24362522</pub-id></mixed-citation>
    </ref>
    <ref id="ref49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sandsveden</surname>  <given-names>M</given-names></string-name>,
<string-name><surname>Borgquist</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Rosendahl</surname>
 <given-names>AH</given-names></string-name>, <string-name><surname>Manjer</surname>
 <given-names>J</given-names></string-name></person-group>. Low thyroid hormone
receptor alpha-2 (thrα-2) tumor expression is associated with unfavorable tumor
characteristics and high breast cancer mortality. <source>Breast Cancer Res</source>
 <year>2021</year>;<volume>23</volume>(<issue>1</issue>):<fpage>117</fpage>.<pub-id pub-id-type="pmid">34930399</pub-id></mixed-citation>
    </ref>
    <ref id="ref50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Watanabe</surname>  <given-names>K</given-names></string-name>,
<string-name><surname>Yamamoto</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Sakaguti</surname>
 <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> A
novel somatic mutation of sin3a detected in breast cancer by whole-exome sequencing
enhances cell proliferation through erα expression. <source>Sci Rep</source>
 <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>16000</fpage>.<pub-id pub-id-type="pmid">30375428</pub-id></mixed-citation>
    </ref>
    <ref id="ref51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nguyen</surname>  <given-names>H</given-names></string-name>,
<string-name><surname>Tran</surname>  <given-names>D</given-names></string-name>,
<string-name><surname>Tran</surname>  <given-names>B</given-names></string-name>,
<etal>et al.</etal></person-group>  <article-title>A comprehensive survey of
regulatory network inference methods using single cell RNA sequencing
data</article-title>. <source>Brief Bioinform</source>
 <year>2020</year>;<volume>22</volume>(<issue>3</issue>):<elocation-id>bbaa190</elocation-id>.</mixed-citation>
    </ref>
    <ref id="ref52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cao</surname>  <given-names>J</given-names></string-name>,
<string-name><surname>Spielmann</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Qiu</surname>
 <given-names>X</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>The single-cell transcriptional landscape of mammalian
organogenesis</article-title>. <source>Nature</source>
 <year>2019</year>;<volume>566</volume>(<issue>7745</issue>):<fpage>496</fpage>–<lpage>502</lpage>.<pub-id pub-id-type="pmid">30787437</pub-id></mixed-citation>
    </ref>
    <ref id="ref53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Trapnell</surname>  <given-names>C</given-names></string-name>,
<string-name><surname>Cacchiarelli</surname>
 <given-names>D</given-names></string-name>, <string-name><surname>Grimsby</surname>
 <given-names>J</given-names></string-name>, <etal>et al.</etal></person-group>
 <article-title>The dynamics and regulators of cell fate decisions are revealed by
pseudotemporal ordering of single cells</article-title>. <source>Nat Biotechnol</source>
 <year>2014</year>;<volume>32</volume>(<issue>4</issue>):<fpage>381</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">24658644</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
